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 Introduction 
 
 
 
1 The extracellular matrix 
 
To form and maintain the function of a complex organ such as the nervous system, an 
interplay between different cellular mechanisms is required. Cells within an organism 
recognize their surrounding, targets and pathways by interactions with the molecules in 
their neighborhood. These molecules can either be diffusible like transmitters or 
hormones, or nondiffusible like cell surface molecules or the content of the extracellular 
matrix. The extracellular matrix is composed of a complex network of macromolecules, 
including laminin, fibronectin, collagen, members of the tenascin family, proteogylcans 
and polysaccharides. These provide support to organs in terms of mechanical strength and 
scaffolding. Furthermore, they participate in cell proliferation, migration, differentiation 
and survival. In the nervous system, the extracellular matrix additionally regulates axonal 
pathfinding, synapse formation and regulation of synaptic efficacy. 
 
 
 
2 The tenascin family 
 
The tenascin family is part of the extracellular matrix. So far five members of the family 
are known, named tenascin-C (TN-C), tenascin-R (TN-R), tenascin-W (TN-W), tenascin-
X (TN-X) and tenascin-Y (TN-Y). The first part of this work describes the identification, 
cloning and characterization of an additional family member, which was named tenascin-
N (TN-N). The second part of this work focuses on the construction and analysis of a 
conditionally targeted TN-R mouse. 
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2.1 The molecular structure of tenascin family members 
 
Tenascins are large multimeric proteins and contain common structural modules. The 
arrangement of these domains is characteristic within this family. Each member has an 
amino-terminal cysteine-rich domain, followed by arrays of epidermal growth factor-like 
(EGF) domains and fibronectin type III-like (FN III) domains. The EGF array always 
starts with one truncated EGF repeat. At the carboxy-terminus a single fibrinogen-like 
(FBG) domain is located. In contrast to the other family members, TN-X und TN-Y 
contain serine- and proline-rich parts, which are inserted in the array of FN III domains. 
An overview of the tenascin family members and their multimeric structure is given in 
Fig. 1. 
Multimerization of TN-C and TN-R has been shown by either Western blot analysis or 
rotatory shadowing images (Erickson and Inglesias, 1984). The latter technique is capable 
to visualize the structure of large molecules in purified protein preparations. The images 
show that TN-C can form hexamers, consisting of six arms emanating from a central core, 
each arm representing a single molecule. The linear EGF portion appears thin and rigid, 
whereas the array of FN III domains is thicker and flexible. A globular domain is present 
at the distal end of the structure and shows the compact appearance of the FBG domain 
(Jones et al., 1989; Spring et al., 1989). For TN-R, only dimeric and trimeric structures 
have been found (Norenberg et al., 1992). The assembly of the TN-C hexamer is a two 
step process, involving formation of trimers and the linkage of trimers into hexamers. 
Trimers and hexamers are stabilized by disulfide bonds of cysteines at the amino-terminal 
part of the tenascins (Kammerer et al., 1998). Because all known tenascins contain a 
domain that mediates mulimerization of TN-C and TN-R, it is likely that all family 
members can form at least trimers. 
The EGF arrays in tenascins are encoded by a single exon and consist of 31 amino acids 
(aa). A single domain contains 6 cysteines in conserved positions, which are capable of 
forming intrachain bonds. These bonds contribute to an exceptionally compact structure, 
that lacks the acidic residues to bind calcium ions, as seen in EGF domains from other 
proteins, e.g. coagulation factors and Notch (Handford et al., 1990; Lendahl, 1998). 
The FN III domains consist of approximately 90 aa with a flexible structure composed of 
seven antiparallel beta-strands arranged in two sheets. FN III domains of TN-C, TN-R, 
and TN-X are known to be altered by differential RNA splicing. For TN-R only a single 
splice variant is known. In contrast, for TN-C at least 27 different FN III variants are 
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generated from 9 spliced FN III domains, as shown by RT-PCR (Joester and Faissner, 
1999). Some splice variants are preferentially expressed during development (Prieto et al., 
1990). Mechanisms that determine the selection of splice sites in tenascins and their 
regulation during development are currently unknown. 
The FBG domain contains polypeptide loops formed by two intrachain disulfide bonds 
(Doolittle, 1984). It represents the most conserved region during evolution and shows the 
ability to bind calcium ions. Evolutionary studies suggest that proteins containing FBG 
domains already played roles in the development of invertebrates before the emergence of 
the domain in the vertebrate lineage (Xu and Doolittle, 1990). 
 
 
 
 
 
Fig. 1: Tenascin family members and their structural motifs. The family consists of 
five members with a typical arrangement of domains. The amount of similar domains is 
indicated by numbers. Alternatively spliced FN III repeats are marked by letters. 
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2.2 Expression profile of tenascin family members 
 
Tenascin family members are expressed in a variety of cell type lineages and tissues. The 
expression is often regulated with respect to both localization and timing. 
Expression in the CNS has been documented for TN-C, TN-R, and TN-Y. TN-C is 
spatially and temporally regulated in the developing CNS (Bartsch, 1996) and is first 
detected at gastrulation and somite formation (Crossin et al., 1986) and later during 
invasion of neural crest cells (Tan et al., 1987). It is mainly secreted by immature and 
reactive astrocytes, but also by subsets of radial glia cells (Kawano et al., 1995) and by 
subpopulations of neurons localized in the hippocampus, spinal cord, and retina (Bartsch, 
1996). TN-C immunoreactivity is often located in a boundary-like expression pattern, 
which correlates with the functional subdivision of neuroanatomical systems (Faissner and 
Steindler, 1995; O'Brien et al., 1992). Although TN-C is absent from most regions of the 
adult brain, the protein persists in areas known to retain a high degree of plasticity, e.g. the 
olfactory bulb and hypothalamus (Theodosis et al., 1997; Gonzalez and Silver, 1994). TN-
C is expressed in the mature PNS at the nodes of Ranvier and at the neuromuscular 
junction. In addition to the expression in CNS and PNS, TN-C is present during 
morphogenesis of the skeleton and vasculature, and occurs in cartilage, tendons, 
connective tissue, spleen, and in the renal interstitium of the kidney (Chiquet and 
Fambrough, 1984; Liakka and Autio-Harmainen, 1992; Truong et al., 1996). 
In contrast to TN-C, TN-R is expressed later during development. TN-R, previously 
designated J1-160/180 or janusin in rodents and restrictin in chicken (Norenberg et al., 
1992; Fuss et al., 1993; Schachner et al., 1994), is expressed predominantly in the central 
nervous system, but a recent publication described TN-R as a minor, transiently expressed 
component of the peripheral nervous system (Probstmeier et al., 2001). It is mainly 
synthesized by oligodendrocytes with highest expression during the period of active 
myelination (Bartsch et al., 1993; Wintergerst et al., 1993) and is detectable at contact 
sites between unmyelinated axons, at the interface between axons and myelinating 
processes of oligodendrocytes, and in myelin sheaths (Bartsch et al., 1993). TN-R is also 
expressed by subpopulations of neurons of retina, hippocampus, and spinal cord and 
highly accumulates at the nodes of Ranvier in the adult (Bartsch et al., 1993; ffrench-
Constant et al., 1986). Furthermore, TN-R is a component of the perineuronal nets 
surrounding neuronal cell bodies of inhibitory interneurons of e.g. cortex and 
hippocampus (Weber et al., 1999). These observations suggest that TN-R is involved in 
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interactions between oligodendrocytes and neurons during myelin formation and axonal 
regeneration (Schachner et al., 1994). 
TN-W has been identified in the zebrafish and is expressed during ontogenetic 
development in embryos, larvae, and juvenile animals. It is present in the lateral plate 
mesoderm and most conspicuously in the presumptive sclerotome (Weber et al., 1998). 
Migrating cells of sclerotomal and neural crest origin also show high levels of expression. 
Furthermore, non-neuronal cells in dorsal root ganglia express detectable levels of TN-W. 
The expression partially overlaps with that of TN-C mRNA, suggesting an involvement of 
both molecules in neural crest and sclerotome migration and in the formation of the 
skeleton. 
As the largest member of the tenascin family, TN-X is predominantly expressed in 
connective tissue, in heart and skeletal muscle, tumor tissues, skin, and in the vicinity of 
blood vessels (Lethias et al., 2001; Hasegawa et al., 1997; Ikuta et al., 2000; Sakai et al., 
1996). Furthermore, a weaker expression was found in the digestive tract, e.g. oesophagus, 
gut, and stomach. The localization of TN-X to blood vessels probably explains the 
occurrence of TN-X mRNA and protein in most tissues examined, whereas in brain, lung, 
and mammary gland no TN-X was detectable (Matsumoto et al., 1994a). The TN-X gene 
shares its chromosomal localization with the major histocompatibility complex class III 
(Bristow et al., 1993; Matsumoto et al., 1994; Rupert et al., 1999). 
TN-Y was identified in chicken and is expressed by different types of muscles, but also in 
lung, kidney, skin and in the nervous system. In the CNS it shows a partially overlapping, 
but also complementary expression pattern with TN-C (Fluck et al., 2000; Hagios et al., 
1999; Hagios et al., 1996; Tucker et al., 1999). 
 
 
2.3 In vitro functions of tenascin family members 
 
The restricted expression of TN-C in boundary-like structures suggested a function for this 
tenascin to form or maintain borders within the CNS. This observation lead to experiments 
which aim to test this notion in vitro. TN-C was initially examined for anti-adhesive and 
inhibitory properties, which became the first characterized functions of a tenascin 
(Faissner and Kruse, 1990; Dorries et al., 1996). Interestingly, TN-R has been shown to 
exhibit similar properties. In the presence of homogenous TN-C or TN-R substrates, cells 
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do not attach to the culture plate or strongly aggregate to minimize their attachment points. 
Furthermore, the anti-adhesive properties of TN-C and TN-R become apparent in 
experiments where outgrowing neurites or migrating cells can choose between tenascin-
containing substrates and substances which support neurite outgrowth and cell migration, 
e.g. laminin or polycations. For example, explants from postnatal day 1 hippocampus send 
out neurites after a few days in culture. The neurites generally avoid the tenascin 
containing substrate and follow the borderline between the permissive and the anti-
adhesive substrate. Thus, the anti-adhesive properties of tenascins induce growth cone 
turning in choice situations (Dorries et al., 1996; Xiao et al., 1996). In addition to effects 
on neurons, TN-C inhibits the adhesion of oligodendroglia and migration of their O2A 
precursor cells (Kiernan et al., 1996). By recombinant expression of selected regions of 
TN-C and TN-R, functionally specialized domains have been identified suggesting an 
interaction of tenascins with many types of receptors. Distinct domains have been 
identified for anti-adhesion and growth cone deflection, for stimulation of axon growth, 
and for the influence on migratory behavior of oligodendrocyte precursors (Joester and 
Faissner, 2001). 
 
 
2.4 In vivo functions of tenascin family members 
 
TN-C is the best characterized member of the family and has been implicated in different 
morphogenetic processes during development, axonal regeneration, synaptic plasticity, 
tumorigenesis, wound healing, and in kidney diseases. However, mice with an inactivated 
TN-C gene have been described as surprisingly normal (Saga et al., 1992, Forsberg et al., 
1996). It was even suspected, that TN-C might be redundant or that TN-R and TN-X are 
upregulated and compensate for TN-C in the knockouts. So far the hypothesis of 
redundancy and compensating mechanisms has not been confirmed. By more detailed 
analysis subtle abnormalities have been observed in the TN-C knockout, demonstrating a 
precise function of the molecule in different tissues. Moreover, the ablation of TN-C 
influences the behaviour. Normal C57BL/6N mice can swim for minutes in a water tank 
without training, whereas TN-C knockouts fail the test and occasionally have to be 
rescued from drowning. Furthermore, they show hyperactive behaviour in open-field test 
and during the day cycle (Fukamauchi et al., 1996). In spite of the normal CNS 
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architecture in these animals, the brain chemistry is altered on the level of 
neurotransmitters (Fukamauchi and Kusakabe, 1997). A recent publication described a 
deficiency in the coordinated migration of neural crest cells, when the translation of TN-C 
mRNA is drastically reduced by knockdown studies in avian embryos (Tucker, 2001). 
TN-C also has functions in the mature peripheral nervous system. It was found that TN-C 
deficient mice have a decreased level of properly myelinated axons compared to control 
animals, and these axons often are in direct contact to other unmyelinated fibers, rather 
than Schwann cells (Cifuentes-Diaz et al., 1998). The end plates are abnormal in knockout 
mice and the terminal sprouting of peripheral nerves, as induced by injections of 
botulinum-A toxin, is reduced to 70 % in the TN-C knockouts (Cifuentes-Diaz et al., 
1998). Some of the observed phenotypes in the peripheral nervous system are in contrast 
to findings of other groups (Moscoso et al., 1998). TN-C is also expressed in many non-
neuronal tissues, where expression is often associated with pathological conditions such as 
neoplasia and inflammation. Studies on TN-C null mutants in inflammatory and 
regenerative processes revealed striking phenotypes. In kidneys, TN-C is expressed 
predominantly in embryonic stages, but also in the adult inner medulla in the vicinity of 
the tubules. Its expression is strongly induced in glomerulonephritis. In the animal model 
for this kidney disease, wildtype mice are able to recover from Habu snake venom induced 
glomerulonephritis. In TN-C knockout mice of three different genetic backgrounds with 
induced glomerulonephritis striking differences have been found in the degree of the 
phenotype depending on the genetic background. In the most extreme case (TN-C 
deficient mice with GRS/A background) the progression of the disease is irreversible and 
all animals died within four months because of renal failure (Nakao et al., 1998). The 
phenotype could be assigned to a defect in mesangial cells of the kidney, a cell type which 
is phagocytic and removes trapped residues from the glomerular filters. 
The expression of TN-R appears to be restricted to the central nervous system, although a 
recent publication described TN-R as a minor, transiently expressed component of the 
peripheral nervous system (Probstmeier et al., 2001). In the central nervous system, TN-R 
is synthesized by oligodendrocytes with the highest expression at postnatal day 14 and it 
accumulates at the nodes of Ranvier. In this context it was shown that TN-R deficient 
mice display a two times decreased axonal conduction velocity in the optic nerve, as 
shown by electrophysological measurements. The morphological analysis of the optic 
nerves of TN-R deficient mice on the ultrastructural level revealed no difference in 
myelination and structure of nodes of Ranvier (Weber et al., 1999). The interaction of TN-
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R with the immunglobulin superfamily adhesion molecule F3/F11/contactin (Pesheva et 
al., 1993) led to the notion that TN-R might also interact with the β2 subunit of the voltage 
gated sodium channels, since a significant homology was found between F3/F11/contactin 
and this β2 subunit (Isom et al., 1995). This postulated interaction has been demonstrated 
by incubating cell cultures expressing the Na+ channels with recombinant fragments of 
TN-R. In these studies an increase in Na+ current by a factor of two has been observed 
(Xiao et al., 1999), whereas morphological and immunocytochemical investigation of the 
distribution, clustering, and number of voltage gated Na+ channels at the nodes of Ranvier 
detected no differences between knockout and wildtype (Weber et al., 1999). In addition, 
the TN-R knockout shows alterations in the extracellular matrix by a disturbed distribution 
of the chondroitin sulfate proteoglycan phosphacan. Furthermore, the perineuronal nets of 
GABAergic interneurons in TN-R deficient mice were clearly different in terms of 
distribution and shape, indicating a role of TN-R in the coordinated formation of these 
mesh-like structures. 
TN-X has been associated to a disease, called the Ehler-Danlos syndrome (Burch et al., 
1997). Due to a deletion arising from a recombination event of TN-X gene with its partial 
duplicate gene, patients were deficient for TN-X expression and suffered from the Ehlers-
Danlos disorder. Most striking findings are the abnormal elastin bodies beneath the 
dermal-epidermal junction, an increase in the perivascular matrix, and uneven packing of 
myelin sheaths of peripheral nerves. The patient’s phenotype is characterized by skin 
hyperextensibility, vascular fragility, and poor wound healing, whereas the disturbed 
myelin formation in the PNS did not lead to an obvious peripheral neuropathy (Burch et 
al., 1997). 
In comparison to other tenascins only little is known about TN-Y and TN-W, and their in 
vivo function still remains to be elucidated. Nevertheless, the overlapping expression of 
TN-W and TN-C in migrating neural crest cells lead to the speculation that TN-W might 
also be relevant for the target finding of neural crest cells as shown for TN-C. 
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3 Conditional gene targeting in mice 
 
 
 
3.1 The construction of gene deficient mice  
 
Gene targeting can be defined as the introduction of site specific modifications into the 
mouse genome by homologous recombination. Since the first description of the 
homologous recombination in mouse embryonic stem (ES) cells (Thomas and Capecchi, 
1987; Doetschman et al., 1988), gene targeting has become a powerful technology to 
study gene function in vivo. The technology utilizes pluripotent murine ES cell lines 
which can be manipulated in vitro. Using these cells, the selection of rare, homologous 
recombination events can be accomplished. In homologous recombination a mutated DNA 
replaces the genomic sequences of the target gene. When such genetically modified ES 
cells are introduced into preimplantation embryos, they can contribute even after extensive 
in vitro manipulation to all cell lineages of the resulting genetically chimeric animal. The 
breeding of germline chimeras results in the transmission of the ES cell derived mutant 
chromosome to their progeny. This allows the establishment of animals heterozygous for 
the desired genetic alteration and by further breeding a homozygous mutant mouse strain. 
The major steps of the method are illustrated in Fig. 2. 
 
 
derivation of
ES cell lines
in vitro
manipulation
collection of
blastocysts
injection of 
recombinant ES
cells into 
blastocysts
blastocysts
reimplantation
chimeric
ES cell derived mice
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Fig. 2: Construction of targeted mouse mutants. Embryonic stem (ES) cells are derived 
from preimplantation embryos and manipulated in vitro by homologous recombination 
with a targeting vector. Recombined ES cells are injected into blastocysts and contribute 
to the developing offspring to generate genetically chimeric mice. Breeding of these mice 
leads to heterozygous and homozygous mice with the desired mutation. 
 
 
 
3.2 ES cell culture 
 
Pluripotent ES cells were first established directly from blastocysts in 1981 (Martin, 1981; 
Evans and Kaufman, 1981) and were later shown to efficiently produce germline chimeras 
even after transfection (Gossler et al., 1986; Robertson et al., 1986). Since then, a fairly 
large number of ES cell lines have been generated which are mainly derived from 129 
mouse substrains or 129 hybrids. There is a smaller number of less frequently used ES cell 
lines derived from other mouse strains, e.g. C57BL/6. All ES cell lines are male, thus the 
germline transmission is usually through male chimeras. The success of a targeting 
approach depends on the ability of the ES cells to colonize the germline at a high 
frequency. To achieve this goal, the ES cells have to be maintained in the state of 
pluripotency by optimal treatment. Mistreated ES cells will easily differentiate from 
pluripotency. Consequently, they may be unable to participate in germline transmission. 
To prevent the differentiation process, ES cells are usually cultured in the presence of 
leukaemia-inhibitory factor (LIF) and on a layer of mitotically inactive feeder cells. These 
feeder cells are derived from embryonic fibroblasts and are treated with mitomycin. In 
spite of the poisoning with mitomycin the cells are able to survive for several days in 
vitro. Feeder cells have to possess the bacterial aminoglycoside phosphotransferase gene 
conferring neomycin/G418 resistance, since this selection marker is used to identify ES 
cells which have undergone recombination with the targeting vector (Muller et al., 1991).  
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3.3 Recombination systems and conventional targeting vectors 
 
The production of a gene targeted mutant strain is a laborious and technically demanding 
effort which often takes more than a year to complete, even longer if technical problems 
are encountered. Therefore, extensive planning and foresight should be given to the 
strategy chosen to elucidate the desired gene function by targeting experiments. The 
construction of the targeting vector, which introduces the mutation into the ES cell 
genome by homologous recombination, is probably the most important step to ensure that 
the gene modification will fulfill the experimental demands. In this context, a flexible 
strategy improves the chance to reach the aim. Most frequently used are conventional gene 
targeting approaches which inactivate the gene function from the beginning of the 
development. Because the potential of each targeting construct is greatly expanded by the 
use of LoxP and/or FRT, these systems should be generally considered for all targeting 
vectors even if the initial goal is simply to inactivate gene function. 
The P1 bacteriphage Cre recombinase is a member of the λ integrase superfamily of site-
specific recombinases and belongs to the few members which do not require cofactors for 
recombination (Argos et al., 1986). It recognizes and mediates site-specific recombination 
between 34 bp sequences referred to as locus of crossover in P1 (loxP). The loxP sequence 
consists of two 13 bp inverted repeats interrupted by a 8 bp non-palindromic sequence 
which specifies the orientation of the overall sequence (Hoess et al., 1982). When two 
loxP sites are placed in the same orientation on a linear DNA molecule, a Cre-mediated 
intramolecular recombination results in the excision of the loxP-flanked (floxed) sequence 
as a circular DNA, which contains the single loxP site. If the two loxP sites are places in 
opposing orientation the floxed sequence will be inverted (Abremski et al., 1983). The 
yeast-derived FLP recombinase shares many features with the Cre recombinase and 
recognizes the so-called FRT sequence. The FLP recombinase operates optimally at 30 
°C, whereas the Cre recombinase has an optimum at 37 °C. In spite of the thermo-
instability of the FLP, its specific recombination has been successfully used to remove a 
FRT flanked selection marker in ES cells. 
In general, the aim of conventional targeting experiments is to replace endogenous 
wildtype sequences which results in complete inactivation of a specific gene. 
Conventional targeting vectors are constructed from a cloned genomic sequence of the 
gene of interest and contain two regions of homology to the genomic locus. Virtually all 
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targeting vectors possess a long and a short arm of homology which flank the region of the 
selectable marker gene, e.g. the bacterial aminoglycoside phosophotransferase (Neo) gene. 
The Neo cassette is often used to replace parts of the coding region of the targeted gene 
with the aim to ablate its expression. Furthermore, the incorporation of the neo gene into 
the genome enables the ES cell to survive the presence of neomycin/G418 in the culture 
medium and thus selects all cells with a randomly integrated or homologously recombined 
targeting vector. The homologous recombinants have to be differentiated from the random 
integrants by PCR or Southern blot analysis. In conventional approaches the 
recombination system is mainly used to remove the selectable marker from the ES cell 
genome prior to injection into blastocysts, which restricts this approach in flexibility. 
 
 
3.4 Conditional gene targeting 
 
Major problems of conventional gene targeting experiments are the lack of temporal 
control and tissue specificity, possible adaptation and compensation mechanisms for the 
missing gene function during embryogenesis and ontogenesis, as well as embryonic and 
neonatal lethality. The combination of gene targeting techniques with site-specific 
recombination systems such as the Cre/loxP system of the bacteriophage P1 or the yeast 
derived FLP/FRT system allows the development of strategies to circumvent these 
problems by restricting the mutation to certain cell types and/or a specific time period, but 
also to introduce large genomic alterations. 
The applicability of the Cre/loxP system for conditional, tissue-specific gene targeting was 
first demonstrated by Gu et al. (1994). Tissue specific gene inactivation can be achieved 
by crossing a mouse line containing floxed alleles at the gene of interest with a mouse 
strain expressing the Cre recombinase under the control of a well characterized tissue-
specific promoter. The number of transgenic mouse lines expressing the Cre recombinase 
under a tissue specific promoter is rapidly growing and is a prerequisite for tissue 
restricted gene inactivation (Nagy, 2000). Additionally, time-controlled expression of Cre 
and time-controlled gene inactivation is achieved by expressing Cre under the control of 
the tetracycline-regulated expression system (Kistner et al., 1996; Shin et al., 1999, 
Yamamoto et al., 2000) or by using ligand-dependent fusion proteins of the Cre 
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recombinase with a mutated hormone binding domain of steroid receptors (Sauer and 
Henderson, 1988; Kellendonk et al., 1996; Buchholz et al., 1998). 
Another well characterized and similar site specific recombination system that has been 
applied to conditional gene targeting is the FLP/FRT system derived from Saccharomyces 
cerevisiae (Andrews et al., 1985; Dymecki, 1996; Koch et al., 2000; Meyers et al., 1998; 
Vooijs et al., 1998). In contrast to the Cre/loxP system, inducible systems have not been 
reported for the FLP/FRT system so far. The use of FLP is more restricted, due to the 
relatively low activity of FLP at 37° C (Buchholz et al., 1996b). Meanwhile, this problem 
has been overcome: a FLP recombinase with improved properties at 37°C has been 
evolved by cycling mutagenesis and termed FLPe (Buchholz et al., 1998). Recently, a 
transgenic mouse line expressing FLPe was shown to be an efficient alternative to the 
Cre/loxP system (Rodriguez et al., 2000), and in the future, broader use and applicability 
of the FLPe/FRT system will be expected. 
Construction of the targeting vector needs detailed information about the gene of interest 
and very often tedious and complicated cloning steps. For conditional gene targeting, the 
vector usually consists of a positive selection cassette flanked by the recognition 
sequences for the site specific recombinase (loxP or FRT) placed in an intron and a third 
recognition sequence placed upstream or downstream in the next intron, thereby marking 
the exon in-between for excision. After identifying homologously recombined ES cell 
clones the selection cassette can be removed by transfection and transient expression of a 
Cre (or FLP) expressing plasmid in vitro. However, three alternative recombination 
products are possible: 1) The so called type I deletion between the outer loxP sites 
removes the selection cassette including the floxed exon, which results in a constitutive 
gene inactivation. This type of clone can be used directly to generate a constitutive 
knockout. 2) The type II deletion which leads to the desired removal of the selection 
cassette leaving the floxed exon. 3) The third type of deletion, which removes only the 
floxed genomic sequence and leaves the selection cassette, can be counterselected by 
screening for neomycin/G418 sensitivity. 
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4 Aim of this work 
 
 
The tenascin family consists of extracellular matrix molecules and in the past decade five 
members of this family have been identified and characterized. They are expressed in 
many types of tissues and contribute to a variety of processes. Two of the tenascin family 
members, namely tenascin-R and tenascin-C, are expressed in the central nervous system 
and show repellent functions on outgrowing neurites and migrating neural cells. In 
contrast to this striking function, gene deficient mice of these molecules have rather 
disappointing phenotypes in the central nervous system. 
 
The aim of this work was to identify possible mechanisms which compensate for the 
lacking target molecule in these knockouts and thus contribute to the unexpectedly mild 
phenotypes. 
The missing link could be a yet not identified tenascin family member, which has similar 
functions as tenascin-R or tenascin-C. Therefore, the major aim of this study was to search 
for a novel tenascin and to characterize its expression pattern and function. 
A frequently discussed problem in conventionally gene targeted mice is the lack of the 
target molecule from the beginning of the development, which might provoke 
compensatory mechanisms. This problem can be overcome by the newly developed 
method of conditional gene targeting. Therefore, it was aimed to construct a conditionally 
targeted tenascin-R mouse line and to ablate its expression at selected time points and in 
specific cell types. 
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 Materials and methods 
 
 
 
1 DNA analysis and manipulation 
 
 
1.1 Preparation of competent bacteria  
 
Bacteria were grown at 37 °C in 100 ml LB medium (10 g/l Bacto-tryptone, 10 g/l NaCl, 5 
g/l yeast extract, pH 7.4) until an optical density of 0.5 was reached at 600 nm. The culture 
was cooled on ice for 5 minutes and transferred to a sterile plastic centrifuge tube. Cells 
were collected by centrifugation at 4000 g for 5 minutes at 4 °C and gently resuspended in 
ice-cold buffer 1 (100 mM RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM 
CaCl2, 15 % glycerol, pH 5.8, sterile-filter). The suspension was kept on ice for 90 
minutes. The cells were centrifuged again and resuspended in 4 ml ice-cold buffer 2 (10 
mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15 % glycerol, pH 6.8, sterile-filter). Aliquots 
were snap frozen in liquid nitrogen and stored at –70 °C for no longer than 6 months. 
 
 
1.2 Transformation of bacteria 
 
Aliquots of competent bacteria were thawn on ice for 10 minutes. Fifty ng plasmid DNA 
was supplemented to the bacteria suspension and incubated for 20 minutes at 4 °C. After a 
heat shock at 42°C for 1 minute and successive incubation on ice for 2 minutes, 800 µl LB 
medium were added and incubated at 37 °C with constant agitation. Cells were collected 
by centrifugation at 1000 g for 2 minutes at room temperature. The transformed bacteria 
were plated on selective agar plates (20 g/l agar in LB medium with antibiotics) and 
incubated overnight to allow single bacteria colonies to grow. 
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1.3 Plasmid propagation in bacteria 
 
The following two bacteria strains were used to propagate plasmid DNA prior to DNA 
isolation procedures: Escherichia coli DH5α (New England Biolabs, Frankfurt am Main, 
Germany) and Escherichia coli XL1-blue (Stratagene, La Jolla, California, USA). 
Between 3 and 15 ml of LB medium (10 g/l Bacto-tryptone, 10 g/l NaCl, 5 g/l yeast 
extract, pH 7.4) were inoculated by a single bacteria colony and incubated at 37 °C 
overnight with constant agitation. One of the following antibiotics was supplemented prior 
to inoculation to select for plasmid containing bacteria: 100 µg/ml ampicillin, 25 µg/ml 
kanamycin, or 25 mg/ml tetracycline. For large scale preparations of DNA a 10 ml 
overnight bacteria culture was used to inoculate 500 ml LB medium. Further incubation at 
37 °C for 4 h resulted in an optical density of 0.6 at 600 nm. 
 
 
1.4 Maintenance of bacterial strains 
 
Selected bacterial strains which contain plasmids of interest were stored in a mixture with 
25 % glycerol and LB medium at –70 °C for up to one year or at –20°C for up to 2 
months. Bacteria grown on agar plates containing an appropriate antibiotic were stored up 
to 6 weeks at 4 °C. 
 
 
1.5 Plasmid DNA purification 
 
The methods used to purify plasmid DNA from bacteria employ alkaline cell lysis of 
bacteria, denaturation of protein by chaotropic salts, and use a glass fiber matrix to 
separate the DNA from contaminants. 
For small scale preparations, bacteria of a 3 ml overnight culture were pelleted by 
centrifugation at 12000 x g for 1 minute at room temperature. Plasmids were isolated from 
the bacteria according to the manufacturer’s protocol (Amersham Pharmacia Mini 
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preparation kit). The DNA was eluted from the glass fiber matrix column by addition of 
50 µl 10 mM Tris-HCl and subsequent centrifugation at 12000 x g for 1 minute. The 
concentration of the eluted DNA was about 0.25 µg/µl as determined by UV-
spectrometry.  
To obtain higher concentrations of DNA, the plasmids from 15 ml bacterial culture were 
purified according to the protocol provided with the Nucleospin Kit (Macherey-Nagel), 
with the exception that the suggested volume of buffers were doubled and the elution 
buffer was warmed to 70 °C prior to usage. Up to 80 µg total DNA per preparation in a 
concentration of 1.5 µg/µl were obtained by the method.  
For large scale preparations with about 500 µg total plasmid DNA, the Maxiprep Kit 
(Qiagen) was used according to the manufacturer’s protocol. 
Further purification of plasmid DNA was achieved by phenol/chloroform protein 
extraction and successive precipitation and washing steps of the DNA in 70 % ethanol at 4 
°C (Sambrook et al., 1989). 
 
 
1.6 Determination of DNA concentration and purity 
 
DNA molecules absorb UV light of a wavelength of 260 nm, whereas proteins absorb 
strongest at 280 nm. Thus, the absorption at 260 nm of purified DNA solutions can be 
converted into DNA concentrations and the ratio of A260/A280 is a measure of the purity of 
the DNA (Sambrook et al., 1989). DNA concentration and purity was determined 
spectrometrically using an Amersham-Pharmacia spectrometer. Absorbance at 260 nm 
need to be between 0.1 and 0.6 for reliable results. DNA preparations with A260/A280 ratios 
of 1.8 to 1.9 were considered to be sufficiently pure for most applications. 
 
 
1.7 Endonuclease restriction analysis 
 
Endonuclease restriction enzymes were used to digest and analyze the sequence of 
plasmids or DNA fragments. The restriction endonucleases were obtained from New 
England Biolabs together with their appropriate buffer sets. The enzyme concentration 
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recommended by the manufacturer’s was doubled and the reaction mixture was incubated 
at 37 °C for 2 h prior to analysis by agarose gel electrophoresis. DNA samples were 
digested successively with two different enzymes that were incompatible with each other. 
 
 
1.8 Dephosphorylation and polishing of plasmid DNA ends 
 
Linearized plasmid DNA was treated with shrimp alkaline phosphatase (SAP, Boehringer 
Ingelheim) to remove the 5’ phosphate group. Fifty ng plasmid DNA was incubated with 1 
u of the enzyme at 37 °C for 2 h. SAP was inactivated by incubation at 65 °C for 15 
minutes. The dephosphorylated plasmid DNA was used for ligation without further 
purification. 
Non-compatible sticky ends of linearized plasmid DNA were converted into blunt ends for 
ligation using the Klenow enzyme (Boehringer Mannheim) according to the 
manufacturer’s instructions. The reaction was terminated by incubation at 70 °C for 10 
minutes.  
 
 
1.9 Ligation of DNA fragments 
 
Ligation of DNA fragments into linearized plasmid DNA was performed by mixing 50 ng 
vector DNA with a threefold to fivefold molar excess of insert DNA. The ligation was 
catalyzed by the T4 ligase (Boehringer Mannheim) in its appropriate buffer set. The 
reaction was incubated overnight at 16 °C for sticky end ligation and at 4 °C overnight for 
blunt end ligation (Sambrook et al., 1989). 
For the ligation of PCR fragments and inserts with a low DNA concentration, the TOPO-
TA cloning Kit (Invitrogen) was used according to the manufacturer’s instructions. 
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1.10 Preparation of genomic DNA 
 
To distinguish between the different genotypes of mice, the tailtip of a mouse was cut off 
and incubated in 400 µl Boston buffer (50 mM Tris-HCl, 50 mM KCl, 2.5 mM EDTA, 
0.45 % NP40, 0.45 % Tween 20, pH 8, 0.1 mg/ml proteinase K) overnight at 55 °C. The 
lysate of the tailtip was vortexed to shear the genomic DNA and centrifuged for 2 minutes 
at 12000 x g at room temperature. One µl of the supernatant, containing a crude 
preparation of genomic DNA, was subjected to a standard PCR with appropriate primer 
combinations under stringent conditions. 
A standard PCR was also used to identify ES cells which had undergone homologous 
recombination or Cre mediate recombination, although the preparation of genomic DNA 
was different: ES cell clones were grown for several days in 96 well plates, washed with 
PBS, and lyzed with 100 µl Boston buffer (see above) overnight at 55 °C. Ten µl 8 M 
LiCl and 100 µl isopropanol was added and incubated overnight at 4 °C with constant 
agitation. The 96 well plate was centrifuged at 3000 x g and the pellet was washed with 70 
% ethanol and dried. The purified genomic DNA was resolved overnight in 100 µl 10 mM 
Tris (pH 8) at 65 °C. One µl was subjected to PCR analysis. 
 
 
1.11 PCR 
 
Amplification of linear DNA fragments was performed by polymerase chain reaction 
(PCR). Thin-walled PCR tubes were used in MJ PCR cyclers with a 50 µl reaction 
mixture. The amplification of DNA was catalyzed by the proofreading Turbo-Pfu 
polymerase (Stratagene) to minimize the incorporation of point mutations due to an error 
rate of the polymerase reaction. The quality of the PCR product was analyzed by gel 
electrophoresis. 
 
 
1.11.1 Standard PCR 
 
The following reaction mixture was used for standard PCR: 
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template    0.5 to 10 ng DNA per reaction 
primer A (5 µM)   3 µl 
primer B (5 µM)   3 µl 
nucleotides (10 mM)   1 µl 
buffer (10x)    5 µl 
Turbo-Pfu polymerase  2.5 units 
ddH2O     ad 50 µl 
 
The following cycling program was used to amplify the desired DNA: 
 
 1) denaturation  94 °C  5 minutes 
 2) denaturation  94°C  1 minute 
 3) annealing   55 – 68 °C 1 minute 
 4) elongation   72 °C  2 minutes per kb DNA 
 5) termination   72 °C  10 minutes 
 6) cooling   4 °C    
 
The amplification procedure (steps 2-4) was repeated 25-35 times. 
When the product length exceeded 3 kb, the elongation time was increased by 1 or 2 
additional minutes. 
The annealing temperature was estimated by calculation of the melting temperature of the 
primer oligonucleotide minus 5 °C, although the annealing temperature often needed 
further optimization. The melting temperature of the primers depends on the GC content 
and was calculated by the following formula: 
 Tm = 4 x (amount of purine bases) + 2 x (amount of pyrimidine bases) 
If the two primers had different melting temperatures, the lower of both was used to 
determine the annealing point.  
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1.11.2 Single colony PCR 
 
The ligation of DNA fragments with low concentrations is a rare event and it can be time 
consuming to identify the desired clone. To screen large amounts of bacterial colonies for 
the desired insert, single colonies were picked from a transformation plate with a sterile 
tooth pick and dotted on a new LB plate. The rest of the colony on the tooth pick was 
lyzed in 30 µl Boston buffer lacking proteinase K (50 mM Tris-HCl, 50 mM KCl, 2.5 mM 
EDTA, 0.45 % NP40, 0.45 % Tween 20, pH 8) at 55 °C for 1 h. To test for the presence of 
the insert DNA, 2 µl of this lysate were subjected to a standard PCR with appropriate 
primers. For plasmid preparation, the colony that contained the desired vector was 
inoculated into LB medium with the colony dotted on the LB plate. 
 
 
1.11.3 Nested PCR 
 
Nested PCR involves two rounds of amplification reactions, in which the product of the 
first round is used as the template DNA of the second round. The second-round PCR is 
performed with two new primers that hybridize to sequences internal to the first-round 
primer-target sequences. If the PCR sensitivity is too low, a nested PCR can increase the 
product yield and specificity. 
Nested PCR was used to specifically amplify the desired product from a mixture of 
amplified DNA fragments obtained after RT-PCR. 
The reaction conditions were as follows: An aliquot of a standard PCR mixture (only 10-
15 cycles) was diluted 1:100 with ddH2O and subjected to the second standard PCR 
reaction as template DNA with different primers for 30 cycles. 
 
 
1.11.4 Touchdown PCR 
 
Touchdown PCR uses a cycling program where varying annealing temperatures increase 
the specificity of PCR. The annealing temperature in the initial cycle should be 5 to 10 °C 
above the Tm of the primers. In subsequent cycles, the annealing temperature was 
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decreased in steps of 1 to 2 °C per cycle until a temperature was reached that is equal to 
the Tm of the primers. 
The touchdown method was used to enhance the specificity of the final PCR product 
amplified from RT-PCR. The applied PCR cycling program started at annealing 
temperatures of 72 °C for two cycles, followed by 2 °C reduction in annealing 
temperatures every second cycle until the desired temperature was reached. From there the 
cycles were repeated 25 to 30 times without annealing temperature changes. 
 
 
1.11.5 Genotyping by PCR 
 
To distinguish between the different genotypes of mice or ES cells, 1 µl of genomic DNA 
was subjected to a standard PCR with appropriate primer combinations under stringent 
conditions. For genomic DNA preparation see section 1.10 of Materials and methods. To 
distinguish between the three possible genotypes (homozygous, heterozygous, and 
wildtype), two primers were constructed to flank the mutated region. Thus, the PCR gave 
rise to three different band patterns, as visualized by agarose gel electrophoresis, and each 
pattern represented one genotype. 
 
 
 
1.12 Purification of DNA from polymerase chain reactions 
 
For direct purification of DNA fragments from the PCR reaction mixture, the Rapid 
purification kit (Life Technologies) was used according to the manufacturer’s instructions. 
The DNA was eluted from the column by addition of 50 µl prewarmed (70 °C) 10 mM 
Tris-HCl (pH 8).  
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1.13 Agarose gel electrophoresis 
 
The integrity and quality of DNA fragments were analyzed in horizontal electrophoresis 
chambers (BioRad) using agarose gels (Gibco). The agarose solution was prepared by 
heating 0.8-2 % (w/v) agarose in TAE buffer (40 mM Tris-acetate, 2 mM EDTA, pH 8.0) 
until the powder was completely dissolved. For analysis of smaller DNA fragments, 1.5 or 
2 % agarose gels were used, whereas larger DNA fragments were analyzed in 0.8 or 1 % 
agarose gels. DNA sample buffer (50 % glycerol in TAE, 0.025 % Orange G dye (Merck)) 
was added to the probes, the gel was covered with TAE buffer and DNA samples were 
pipetted into the gel pockets. The gel was run at the constant voltage of 10 V/cm gel 
length until the Orange G dye had reached the end of the gel. The separated DNA 
fragments were visualized under UV light after incubation of the gel in ethidiumbromide 
staining solution (0.5 µg/ml TAE) for 30 minutes. Gels were documented with the 
E.A.S.Y. UV light system (Herolab, Wiesloh, Germany). 
 
 
1.14 Purification of DNA from agarose gels 
 
Gel electrophoresis of DNA fragments provided not only a method to analyze the quality 
or integrity of DNA, but was also a powerful method to purify DNA fragments of 
different lengths by separation. Separated DNA fragments were excised from the agarose 
gel after ethidiumbromide staining. The DNA was purified with the Rapid Gel Extraction 
Kit (Life Technologies) according to the manufacturer’s instructions. The fragments were 
eluted from the glass fiber matrix column by addition of 50 µl of pre-warmed (70 °C) 10 
mM Tris-HCl (pH 8.0). DNA concentration was determined by UV light spectrometry. 
 
 
1.15 Sequencing of DNA 
 
DNA sequencing was performed by the sequencing facility of the ZMNH using a Abi 
Prism Sequencer 100, model 377. Vector DNA (1 µg) or PCR product (0.1 µg) were 
mixed with 10 µM appropriate primer before analysis. 
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1.16 Targeting vector construction 
 
To generate a conditionally TN-R deficient mouse line, a targeting vector of the 
replacement type was constructed from parts of the 5’ genomic sequence of the TN-R 
gene. A genomic clone, which contained the 5’ end of tenascin-R, was kindly provided by 
P. Weber. The clone was isolated from a isogenic λGEM11 genomic library constructed 
from 129/SV(ev) embryonic stem cell DNA (Muller et al., 1994) by hybridization with a 
500 bp cDNA fragment that recognized the EGF domains in tenascin-R. 
This genomic clone was characterized by systematic restriction enzyme analysis. Different 
enzymes were tested for their ability to cut the DNA only once. Afterwards, the position 
of single cutters on the genomic clone was determined by double digestion with a 
restriction endonuclease from the multiple cloning site of the vector backbone. A 11 kb 
fragment flanked by EcoRI was identified and subcloned in the vector pBlueAmp-KS. 
From this 11 kb fragment, two subfragments flanked by either EcoRV/EcoRV or 
EcoRV/XhoI restriction sites, were both isolated and ligated into pBlueCam-KS. This 
cloned genomic DNA (7 kb) contained the 5’ end of TN-R including exon 1 and 2 and 
was used as the targeting vector backbone. The targeting vector backbone was then 
equipped with a neo selection gene, loxP, and FRT sites at appropriate positions. 
 
 
1.17 Southern blot analysis 
 
To identify ES cells which had undergone a desired homologous or Cre mediated 
recombination, Southern blot analysis was performed. The protocol resembles the 
classical capillary blot (Sambrook et al., 1989). 
From each ES cell clone 5-10 µg genomic DNA was digested with 50 to 100 u of an 
appropriate restriction endonuclease and separated by electrophoresis in a 0.8 % agarose 
gel. The DNA was depurinated by incubation of the gel in 0.25 M HCl (10 minutes, room 
temperature) and denaturated 30 minutes in a solution containing 1.5 M NaCl and 0.4 M 
NaOH. The capillary blot procedure was used to transfer the DNA onto Hybond-N(+) 
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membranes (Amersham Pharmacia) by 0.4 M NaOH solution. The genomic DNA was 
hybridized with a radioactively labelled 400 bp probe in hybridization solution (0.5 ng 
labelled probe, 5x Denhardts, 5x SSPE, 0.5 % SDS, 100 µg/ml denaturated salmon sperm 
DNA) overnight at 65 °C. The probe was derived from the 3’ part outside of the targeting 
vector. Unspecific bound probe was washed from the membrane by two washing steps 
with 2x SSPE/0.1% SDS for 15 minutes followed by 1x SSPE / 0.1 % SDS for 30 minutes 
at 65 °C. Signals were detected by overnight exposure of the membrane to Kodak-Xomat-
AR film in a cassette equipped with amplifier screens. 
 
 
 
2 In silico analysis of DNA and protein 
 
DNA sequence data were processed and assembled using the Lasergene biocomputing 
software package (DNAStar) including the programs Editseq, Seqman II, Primerselect, 
Mapdraw, Megalign, Protean, and Genquest. 
Protein structures were predicted with the internet accessible programs SMART and 
PFAM tools (http://smart.embl-heidelberg.de, http://pfam.wustl.edu/), which helped to 
identify domains by conserved amino acids. Putative target regions of posttranslational 
modifications were analyzed with the PSORT program (http://psort.nibb.ac.jp/). 
 
 
 
3 RNA analysis and manipulation 
 
 
3.1 mRNA preparation  
 
The described method is designed for rapid isolation of messenger RNA (mRNA) directly 
from crude extracts of animal tissues without a prior extraction of total RNA. The method 
relies on the base pairing between the poly (A)+ residues of mRNA and the oligo(dT) 
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covalently bound to the purification matrix surface. The matrix consists of 
superparamagnetic beads, which can be collected by magnetic force. 
Dissected tissues from adult mice were immediately frozen in liquid nitrogen and ground 
to powder in frozen state. Fifty mg of tissue powder was further processed with the 
Dynabeads mRNA Direct Kit (Dynal) to yield pure mRNA. The tissue was resuspended in 
1.25 ml lysis-buffer (100 mM Tris-HCl, pH 8, 500 mM LiCl, 10 mM EDTA, 1 % SDS, 5 
mM DTT) and genomic DNA was sheared by repeated passages through a hypodermic 
needle with a diameter of 0.9 mm to achieve complete homogenization. After 2 minutes of 
centrifugation at 14,000 × g and room temperature the supernatant was mixed with 
superparamagnetic Oligo(dT)25-Dynabeads and incubated for 5 minutes at room 
temperature to allow binding of polyadenylated RNAs to the beads. A magnetic device 
collected the beads and contaminants were removed by successive washing steps with a 
modified buffer set (buffer I: 100 mM Tris, pH 8, 500 mM LiCl, 5 mM EDTA, 0.5 % 
SDS; buffer II: 50 mM Tris, pH 8, 500 mM LiCl, 5 mM EDTA, 0.5% SDS; buffer III: 50 
mM Tris, pH 8, 500 mM LiCl, 2.5 mM EDTA; buffer IV: 10 mM Tris, pH 8, 150 mM 
LiCl, 1 mM EDTA) at room temperature. The mRNA was eluted in 10 mM Tris, pH 8, at 
65°C, aliquoted, and immediately frozen in liquid nitrogen. Aliquots were thawn at 4°C 
directly before application to reverse transcription or Northern blot analysis. The 
concentration of mRNA was tested by UV-light-spectrometry. Possible degradation 
products of the mRNA were detected by agarose gel electrophoresis. 
 
 
3.2 Determination of RNA concentration and quality 
 
RNA molecules absorb UV light at wavelength of 260 nm. In contrast, the absorption at 
280 nm is more specific for proteins. This can be utilized to determine the RNA 
concentration and purity in solution. Thus, the conversion of RNA absorption into 
concentrations and the determination of the ratio A260/A280 provides a simple method to 
measure the quantity and quality of RNAs (Sambrook et al., 1989). RNA concentration 
and purity was determined spectrometrically using an Amersham-Pharmacia spectrometer. 
Absorbance at 260 nm need to be higher than 0.1 but less than 0.6 for reliable results. 
RNA preparations with A260/A280 ratios of 1.9 to 2.0 were considered to be sufficiently 
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pure for most applications. The integrity of mRNA preparations was further visualized by 
agarose gel electrophoresis. 
 
 
3.3 Reverse transcription 
 
The reverse transcriptase (RT) is a multifunctional enzyme with three distinct enzymatic 
activities: a RNA-dependent DNA polymerase, a hybrid-dependent exoribonuclease 
(RNase H), and a DNA-dependent DNA polymerase. Since reverse transcriptases are 
generally derived from retroviruses, the combination of these three activities in vivo 
allows transcription of the single stranded RNA into double stranded DNA for retroviral 
infection. For reverse transcription in vitro, the first two activities are utilized to produce 
single-stranded cDNA. 
Purified mRNA was transcribed to first strand cDNA using the RNase H deficient 
SuperScript II reverse transcriptase (Life Technologies) according to the manufacturer’s 
instructions. Briefly, 500 µg/ml oligo (dT)18 or sequence specific primer was annealed to 
50-500 ng of mRNA by initial heating to 70 °C and slow cooling to room temperature. 
The first strand cDNA synthesis was performed at 42 °C for 1 h in the presence of DTT. 
Amplification of some PCR targets required the removal of the RNA complementary to 
cDNA by adding 2 units of RNase H (Life Technologies). 
For cDNA synthesis of samples with very low RNA concentration (1-50 ng), the 
Sensiscript reverse transcriptase (Qiagen) was used according to the manufacturer’s 
instructions. Since the Sensiscript enzyme has an endogenous RNase H activity, the 
cDNA could be directly applied to PCR reactions.  
 
 
3.4 5’-RACE 
 
Rapid amplification of cDNA ends (RACE) is a PCR-based technique which facilitates 
the cloning of full-length cDNA sequences when only a partial sequence is available. 
cDNA clones frequently lack the 5’ ends due to incomplete reverse transcription. Classical 
5’RACE protocols are designed to add adaptor sequences to all 5‘ cDNA ends including 
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the truncated or degenerated cDNAs. The major disadvantage of these protocols is that no 
selection for the full length 5’ end is included. These limitations of the classical 5’-RACE 
method can be overcome by RNA ligase mediated RACE (RLM-RACE). RLM-RACE is 
designed to ligate RNA adaptor sequences to the capped and thus full length RNA only. 
The protocol removes the 5’ phosphate group of incomplete or fragmentized mRNA 
molecules by phosphatase treatment and thus inactivates these for ligation. The following 
decapping of the full length mRNA by pyrophosphatase leaves a 5‘ monophosphate group 
at complete mRNAs. During the ligation of the synthetic RNA adaptor most of the full 
length decapped RNA acquires the adaptor sequence, whereas the dephosphorylated RNA 
is inactivated for this ligation step. Using one gene specific primer in addition to an 
adaptor specific primer for PCR amplification (after cDNA synthesis), the complete 5’ end 
of the desired cDNA can be obtained. 
To clone the 5‘ end of TN-N, FirstChoice RNA Ligase Mediated RACE (RLM-RACE kit, 
Ambion) was performed according to the manufacturer’s recommendations. The mRNA 
was prepared from kidney and brain and the TN-N specific primer sequence was: 5‘-
agcaagccggtgatgtcatag-3‘. Cycling conditions for 5’-RACE were: 94 °C for 30 seconds, 
followed by annealing at 60 °C for 30 seconds, and 2.5 minutes of elongation at 72°C. 
These steps were repeated 30 times to amplify a single band specific for the complete 5’ 
end of TN-N. 
 
 
3.5 3’-RACE 
 
In 3’ RACE experiments a defined sequence is added to the 3’ end of all mRNA 
molecules. This modification is achieved by priming the cDNA synthesis with an oligo 
(dT) primer which contains a specific adaptor sequence. PCR experiments using an 
adaptor specific primer together with a gene specific primer can amplify the complete 3’ 
end of the desired cDNA.  
For 3‘RACE, the first strand cDNA was synthesized from purified mRNA using 
Superscript II (Life Technologies) reverse transcriptase and an modified adaptor primer 
(5’-atcgatggtcgacgcatgcggatccaaagcttgaattcgagctc(t)17-3’). Subsequent standard PCR with 
an adaptor-specific primer (5’-atcgatggtcgacgcatgcggatcc-3’) and a TN-N specific primer 
(5’-gccggggatgctctcac-3’) yielded a product of 1300 bps that was gel purified, cloned into 
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pCR2.1, and subjected to sequence analysis. The 3’ clone of TN-N contained the FBG 
domain and a 993 bp untranslated region (UTR). 
 
 
3.6 Discovery and identification of a cDNA encoding TN-N 
 
Screening of the EST database at the National Center for Biotechnology Information using 
the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) revealed EST sequences with 
significant homology to known tenascins. One of these EST clones (GenBank accession 
number W29478) was ordered from the Resource Center/Primary Database (Berlin, 
Germany) and sequenced to obtain the complete sequence of the 1kb cDNA insert. To 
connect the sequences of the ESTs W29478 and W35807, two primers were derived 
(primer1: 5’-atggcaggacagaaattgatggac-3’, corresponding to EST W29478; primer2: 5’-
tggaaaaggggcagttaaaaatagc-3’, corresponding to EST W35807) and applied in a standard 
PCR experiment to amplify a 4 kb fragment from brain and kidney cDNA. The fragment 
was gel purified, cloned into pCR2.1 (Invitrogen), and sequenced. The sequence contained 
a large portion of the novel tenascin including 3 EGF domains and 10 FN III domains. To 
obtain the complete 5’ and 3’ ends, RACE experiments were performed. 
 
 
3.7 Discovery of a splice product of TN-N 
 
An alternatively spliced cDNA of TN-N was identified by RT-PCR that utilized mRNA 
preparations from hippocampi and kidneys of 3-month-old mice. In these experiments, 
reverse transcription was primed with the oligonucleotide (dT)18. Subsequent PCR with a 
primer corresponding to FN III domain 1 (5’-accctgcgcaacgtgaagaaagac-3’) and a primer 
corresponding to FN III domain 10 (5’-gacagtgctgctcttctccttcctca-3’) simultaneously 
amplified the full length cDNA and a shorter splice variant of TN-N. The splice variant 
lacked the third FN III domain of TN-N. All PCR experiments were carried out with 
PfuTurbo polymerase (Stratagene) according to the manufacturer’s instructions to 
minimize the frequency of point mutations. Cycling conditions were: 95 °C for 1 minute, 
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followed by annealing at 60 °C for 1 minute, and followed by 4 minutes of elongation at 
72 °C. These steps were repeated 40 times. 
 
 
3.8 Northern blot analysis 
 
Northern blot analysis was performed to detect the size and tissue distribution of mRNA 
molecules and to detect developmental differences in mRNA levels. The protocol 
described here resembles the classical capillary blot (Sambrook et al., 1989) to transfer 
size separated mRNA onto a membrane. The mRNA was detected by hybridization with a 
radioactively labelled gene specific probe. Briefly, 2 µg of different mRNA samples were 
resolved in formaldehyde and formamide containing sample buffer and were separated in 
a formaldehyde agarose gel at 80 V for 3 - 4 h at room temperature. The capillary blot was 
assembled to transfer the ribonucleotides overnight by 10 × SSC at room temperature to 
Hybond XL nylon membrane (Amersham Pharmacia). Ribonucleotides were crosslinked 
to the membrane by UV light exposure. The mRNA was hybridized with two specific 
cDNA probes coding either for the first and second FN III domain of TN-N or for the 
second exon of TN-R. The membranes were stripped before reuse by incubation with a 
boiling 0.1 % SDS solution for 5 minutes. 
The distribution of TN-N transcripts in 3-month-old mouse tissues was evaluated using 
the Mouse Multiple Tissue Northern Blot (Clontech). A 350 bp PCR fragment comprising 
the region encoding FN III domains 1 and 2 of TN-N was labelled with 32P (1 × 108 
cpm/µg) by random priming (Megaprime-Kit, Amersham Pharmacia Biotech) and 
hybridized to the membrane in ULTRAhyb buffer (Ambion) at 42°C overnight. The blot 
membrane was washed twice with a high salt solution (2 × SSC, 0.1 % SDS) at 68 °C for 
15 minutes and once with a low salt solution (0.1 × SSC, 0.1 % SDS) at 42 °C for 5 
minutes. Kodak X-Omat AR films were used to detect the signals after overnight exposure 
at –70 °C in a cassette equipped with amplifier screens. 
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3.9 In situ hybridization analysis 
 
For in situ hybridization analysis, 35S labelled riboprobes corresponding to the TN-N 
specific 350 bp PCR fragment described above were generated from plasmid templates 
with the Maxiscript Kit (Ambion) according to the manufacturer’s instructions. 
Cryosections of the respective tissues were fixed with 4 % paraformaldehyde in PBS for 
10 minutes at 4 °C, washed twice with PBS for 5 minutes at room temperature, dehydrated 
by successive incubations in 60 %, 80 %, 90 %, 95 % and 100 % ethanol, chloroform, and 
100 % ethanol, and air dried. After 3 hours of incubation with prehybridization solution 
(750 mM NaCl, 25 mM PIPES, 25 mM EDTA, pH 6.8, 0.1 % Ficoll, 0.1 % 
polyvinylpyrrolidone, 0.1 % BSA, 0.2 % SDS, 10 mM DTT, 50 % deionized formamide, 
denatured yeast RNA and sperm DNA, each 250 µg/ml) at 50 °C, the cryosections were 
transferred to hybridization solution (prehybridization solution with 10 % dextran sulfate 
and 1 × 107 cpm/ml of the labelled probe) and incubated overnight at 50 °C. Samples were 
washed in 4 × SSC for 5 minutes at room temperature, incubated in RNase A containing 
solution (500 mM NaCl, 10 mM Tris, pH 7.5, 1 mM EDTA, 40µg/ml RNase A) at 37 °C 
for 30 minutes and washed with the same solution lacking RNase A at 37 °C for 30 
minutes. The samples were washed twice with 2 × SSC at 50 °C prior to signal detection 
by overnight exposure to Kodak X-Omat AR films. Autoradiographic signals in brain 
were detected by exposure to film for 4 days. For more detailed detection of the signal, the 
hybridized cryosections were dipped in Kodak-NTB3 emulsion, incubated for 3 weeks, 
developed, and counterstained with Mayer’s hemalum reagent (Merck). Bone and 
cartilage were visualized by staining with Alizarin-Red S / Toluidine-Blue O (Sigma). 
 
 
 
4 Protein analysis 
 
 
4.1 Protein extraction 
 
Protein extracts were prepared from snap frozen tissues. High protein concentrations were 
obtained by homogenization of 30 % (w/v) tissue in RIPA buffer (50mM Tris, pH 7.5, 150 
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mM NaCl, 1 mM EDTA, pH 7.5, 0.2 % NP-40, 1 × Complete Protease Inhibitors (Roche 
Diagnostics)) at 4 °C. The homogenate was centrifuged at 20,000 × g and 4 °C for 30 
minutes to remove insoluble components. The protein content of the cleared supernatant 
was determined and appropriate amounts were subjected to Western blot analysis. 
 
 
4.2 Determination of protein concentration 
 
To ensure comparable protein concentrations in Western blot analysis, the protein extracts 
were subjected to protein concentration determination. Protein concentration was 
determined in 96 well plates using the Micro BCA Reagent (Pierce) according to the 
manufacturer’s instructions. 
 
 
4.3 Protein analysis by Western blot 
 
Separation of proteins was performed by discontinuous SDS polyacrylamide gel 
electrophoresis (SDS-PAGE; Laemmli, 1970) using the Mini-Protean III system (Biorad). 
The different proteins were focused on top of the running gel by a 0.8 cm stacking gel 
containing 5 % (v/v) acrylamide (3,77 ml deionized water, 0.32 ml 1 M Tris (pH 6.8), 
0.05 ml 10 % SDS, 0.83 ml 30 % acrylamide:bis (29:1), 0.025 ml 10 % APS, 0.007 ml 
TEMED), followed by separation of the proteins in a 4.5 cm running gel with 10 % 
acrylamide (3.92 ml deionized water, 5.26 ml 1 M Tris (pH 8.8), 0.14 ml 10 % SDS, 4.7 
ml 30 % acrylamide:bis (29:1), 0.07 ml 10 % APS, 0.007 ml TEMED). The protein 
samples were boiled for 10 minutes in sample buffer (0.312 M Tris-HCl, pH 6.8, 10 % 
SDS, 5 % β-mercaptoethanol, 50 % glycerol, 0.15 % bromphenol blue) prior to analysis. 
The samples were then loaded in amounts of 1 ng to 100 µg per lane and the gel was run 
at constant 80 V for 10 minutes followed by constant 140 V for approximately 1 h until 
the bromphenol blue reached the end of the gel. 
The separated proteins were transferred to a nitrocellulose membrane (Protean 
nitrocellulose BA 85, Schleicher&Schüll) using the Mini Transblot apparatus (Biorad) 
according to the manufacturer’s instructions. Proteins were blotted electrophoretically at 4 
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°C in blot buffer (25 mM Tris-HCl, 192 mM Glycin) at constant voltage (80 V for 2 h or 
30 V overnight). A pre-stained marker (BenchMark, Gibco) was used to determine the 
molecular weight of the separated proteins and to monitor the electrophoretic transfer. 
For immunological detection of proteins, nitrocellulose membranes were washed once in 
TBS (10 mM Tris-HCl, pH 8, 150 mM NaCl) and incubated in 8 ml milk powder solution 
(2 % in TBS) for 1 h at room temperature. The antibody was diluted in milk powder 
solution and incubated for 2 h at room temperature with constant agitation. Unspecifically 
bound primary antibody was removed by washing the membrane 5 times in TBS for 5 
minutes each. Secondary antibody was applied in milk powder solution for 1 h and the 
membrane was washed again 5 times with TBS. Signals were detected using horseradish 
peroxidase coupled species Ig specific secondary antibodies (Santa Cruz Biotechnology) 
and ECL reagent (Amersham Pharmacia) on Biomax ML film (Kodak). 
 
 
4.4 Coomassie staining of polyacrylamide gels 
 
Following the SDS-PAGE separation of proteins, the gels were stained by Coomassie blue 
(40 % ethanol, 10 % acetic acid, 0.1 % Serva blue R250) for 1 h at room temperature. 
Unspecific staining was washed out in stripping buffer (0.5 M NaCl, 0.5 M acetic acid) for 
2 h at room temperature or until the gel became transparent. 
 
 
4.5 Densitometric evaluation of band intensities 
 
Band densities were quantified to compare protein amounts present in a single band which 
were detected by coomassie staining. The Scion Image program (Scion Corporation, USA) 
was used to analyze the relative band density from a digitized scan of the coomassie 
staining pattern according to the manufacturer’s instructions. 
 
 
                                                                                                             Materials and methods 
34 
4.6 TN-N antibody production and immunoblot analysis 
 
A polyclonal TN-N antibody was generated by immunization of rabbits with a peptide 
(TVPKSRDPKSRYDITC) that corresponded to the second FN III domain of TN-N. The 
peptide was coupled to key-hole limpet hemocyanin as a carrier protein (Eurogentec). 
Serum was taken after the third boost and stored at –20 °C.  
To determine all bands detected by the antibody, crude protein extracts were prepared for 
Western blot analysis from snap frozen tissues and the homogenate was centrifuged at 
10,000 × g and 4 °C for 5 minutes to remove large insoluble components only. Equal 
amounts (10 to 100 µg) of the supernatants, which contained soluble and insoluble 
proteins, were subjected to SDS-PAGE (Laemmli, 1970). TN-N was detected with a 1:500 
dilution of the polyclonal TN-N antibody. 
 
 
4.7 Evaluation of the specificity of the TN-N antibody 
 
To evaluate the specificity of the antibody, a 1:500 dilution was incubated 15 minutes at 
room temperature with 50 µg of the TN-N peptide used for immunization. This incubation 
abolished the detection of the TN-N specific band at 170 kD. Furthermore, the preimmune 
serum was used as a control in 1:500 dilutions. 
Recombinant TN-N fragments (10 ng purified and concentrated protein) were subjected to 
Western blot analysis under denaturing conditions using the TN-N antibody. These 
experiments confirmed the specificity of the antibody for the peptide sequence located in 
the FN III domain 2 of TN-N. 
 
 
4.8 Expression and purification of recombinant TN-N fragments 
 
To address the question whether the two splice variants of TN-N exhibit different 
functions in cell culture assays, a library of recombinant proteins from the FN III region of 
TN-N was generated. 
                                                                                                             Materials and methods 
35 
Subfragments of the TN-N protein were expressed in E.coli: the corresponding regions of 
the cDNA were amplified by standard PCR procedures and cloned into the expression 
vector pQE30 (Qiagen) to provide the recombinant fragments with an amino-terminal His-
tag. Primers were designed to amplify the desired FN III domains of TN-N and to contain 
appropriate restriction sites to facilitate directional cloning of the amplicons into pQE30. 
Primer sequences were: 
 
FN III-2-forward:  5’-atatgcatgccctcagcatctacttgccacc-3’; 
FN III-2-reverse: 5’-tccccccgggtcattctgtcctgccattcaggag-3’; 
FN III-4-reverse: 5’-tccccccgggtcagctctcccgatcgcctttctc-3’; 
FN III-5-forward: 5’-atatgcatgcgacatcgacagccccaaaaactt-3’; 
FN III-7-reverse: 5‘-gggaagctttcatggggctttggtgctggtcttc-3‘. 
 
TN-N cDNA fragments encoding the second FN III domain were amplified with primers 
FN III-2-forward and FN III-2-reverse, a fragment corresponding to FN III 5 to 7 was 
obtained by PCR with primers FN III-5-forward and FN III-7-reverse, and the 
combination of primers FN III-2-forward and FN III-4-reverse yielded a PCR fragment 
encoding either FN III 2 to 4 (when full length cDNA was used as a template) or FN III 2 
+ 4 (when the splice variant cDNA served as a template). 
Expression and purification of the recombinant protein fragments in bacteria were 
achieved following the manufacturer’s instructions (The QIAexpressionist, Qiagen). 
Briefly, recombinant plasmid clones were used to transform competent M15[pREP4] 
E.coli cells. To determine the target protein solubility 10 ml LB medium was inoculated 
from the glycerol stocks and grown until the OD600 was 0.6. Protein expression was 
induced by adding isopropyl-D-thiogalactopyranoside (IPTG) to 1mM. After 4 h of 
growth at 37 °C, the bacteria were harvested and lyzed by sonification in buffer 1 (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and centrifuged at 10,000 × g. The 
supernatants and the pellet fraction were analyzed by 12 % SDS-PAGE under reducing 
conditions and Coomassie staining. All FN III domains were purified from supernatants of 
large scale preparations as soluble proteins. Fragments were purified by affinity 
chromatography on a nickel-chelate-resin (Ni-NTA beads, Qiagen). The purified proteins 
were extensively dialyzed against PBS and concentrated with Centricon filter devices 
(Millipore). Aliquots were stored at –20 °C and thawn only once at 4 °C directly before 
use. 
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5 Cell culture 
 
 
5.1 Preparation of dissociated hippocampal neurons 
 
The preparation of hippocampal neuron cultures was essentially based on the method 
described elsewhere (Dityatev et al., 2000) and was performed in cooperation with G. 
Dityateva. Briefly, the hippocampi of 1 to 3 day old mice were isolated, cut into small 
pieces, and treated with trypsin (6 mg / 1.8ml) and DNase I (1.5 mg / 1.8 ml) in Ca2+ and 
Mg2+ free Hank’s balanced salt solution for 10 minutes at room temperature. The cells 
were dissociated by pipetting up and down with three fire-polished Pasteur pipettes with 
sequentially smaller diameter. After the dissociation, the cells were centrifuged twice at 
100 x g for 15 minutes at 4 °C to remove cellular debris and plated at a density of 700 
cell/mm2 on glass cover slips (Assistant, Germany) coated with poly-L-lysine (100 µg/ml) 
and laminin (20 µg/ml). For the first two days, the neurons were maintained in culture 
medium (Eagle’s MEM containing 5 g/l glucose, 2 mM glutamax I, 100 µg/ml bovine 
transferring and insulin, 5 µg/ml gentamycin, and 10 % tested horse serum). Starting from 
day 3, gentamycin was omitted, and the concentration of serum was reduced to 5 %. The 
culture medium was supplemented with 5 µM cytosine-arabinofuranoside and 2 % B-27 
supplement (Life Technologies). 
 
 
5.2 Indirect immunofluorescence 
 
Dissociated hippocampal neurons (Dityatev et al., 2000) were cultured for 5 to 6 days. 
Cultures were fixed in 4 % paraformaldehyde for 10 minutes, washed extensively with 
PBS, and incubated with 1 % BSA for 1 h. The TN-N antibody and the preimmune serum 
(both diluted 1:500) were incubated with the cultures for 1.5 h at room temperature. 
Antibody binding was detected after washing with PBS by immunofluorescence labelling 
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with a Cy3 conjugated secondary antibody (Dianova). Images were taken with the Zeiss 
laser scanning microscope 510. 
 
 
5.3 Hippocampal explant culture 
 
Hippocampi were prepared from newborn C57BL/6J mice in dissection medium (powder 
medium Sigma H 2387 without Ca2+ and Mg2+, 4.2 mM NaHCO3, 5.8 mM MgSO4, 10 
mM HEPES, 33.3 mM D-glucose, 5 µg/ml gentamycin, 0.3 % BSA, fraction V) at 4 °C. 
From 400 µm hippocampal slices CA3 region explants were prepared in culture-medium 
(MEM Eagle Medium, 28 mM D-glucose, 0.1 mg/ml transferring, 0.025 mg/ml insulin, 
2µM glutamax I, 5 µg/ml gentamicin, 10% fetal calf serum). 
The explants were oriented around the substrate border which was prepared as described 
elsewhere (Becker et al., 2000). Briefly, glass bottom cell culture plates (MatTek) were 
successively coated with poly-D-lysine (PDL; 2.5 mg/ml), nitrocellulose (0.8 cm2/ml 
dissolved in methanol), and PDL (2.5 mg/ml). TN-N fragments were spotted onto a 
defined area at a concentration of 100 µg/ml in a mixture with 100 µg/ml rhodamine-
coupled BSA (Molecular Probes). Prior to placement of CA3 region explants around the 
protein coated area, the complete surface was coated with laminin at concentrations of 1.7 
µg/ml. The explants were maintained in culture for 4 days before analysis. The substrate 
border was detected by the fluorescence of rhodamine-coupled BSA (Molecular Probes). 
Phase contrast microscopy was used to analyze neurite outgrowth and cell migration. 
Experiments were repeated at least 3 times. 
 
 
5.4 Fibroblast cell culture 
 
Fibroblasts were cultured to serve as a feeder cell layer for ES cells. Fibroblasts were 
isolated from 13-day-old mouse embryos which contained a neomycin resistance gene. 
The blood organs of the embryo were removed and the rest was minced in PBS. The 
minced tissue was treated with trypsin/EDTA (10 % (w/v) trypsin, 1 mM EDTA in PBS) 
for 10 minutes at 37 °C. The digestion was stopped by addition of 1 volume MEF medium 
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(DMEM with glucose and glutamax I, 9 % FCS, 1 x MEM non essential amino acids, 50 
IU/ml penicillin, 50 µg/ml streptomycin, all ingredients from Gibco/BRL). The mouse 
embryonic fibroblasts (MEF) were collected from the supernatant by centrifugation  at 
350 x g for 5 minutes at room temperature, resuspended in MEF medium, and propagated 
by repeated passages every 3 days (splitted 1:3) for maximally 6 times. Aliquots were 
stored in liquid nitrogen. 
Mitotically inactivated feeder cells were prepared for ES cell culture: MEF cells were 
grown on gelantinized culture dishes (incubate 0.1 % gelantine in PBS for 1 h at room 
temperature on the culture dish) until a confluent cell density was reached. An incubation 
with 10 µg/ml mitomycin C for 3 h at 37 °C in humidified atmosphere blocked the mitosis 
of the MEFs. The cells were resuspended and seeded at cell densities of 5 x 104 cells/cm2 
to serve as feeder cell layers for ES cell culture. 
 
 
5.5 ES cell culture 
 
Targeted ES cells were used as pluripotent vehicles to deliver their genome which 
contained the desired mutation. ES cells were received in cooperation with the Nagy Lab 
(http://www.mshri.on.ca/nagy). The ES cells were prepared and propagated from 3.5-day-
old blastocysts of the 129/SV mouse line and cultured at 37 °C in humidified atmosphere 
on mitotically inactive feeder cells. The culture medium (DMEM with glucose and 25 mM 
hepes, 15 % ES qualified FCS, 1 x glutamine, 1 x non essential amino acids, 1 mM 
pyruvate, 50 IU/ml penicillin, 50 µg / ml streptomycin, 0.1 mM mercaptoethanol, 1000 u / 
ml LIF) was changed every second day in parallel with passage procedures. 
After transfection of ES cells with the targeting vector and selection for neomycin/G418 
resistance, only cell clones of round shape with sharp borders were selected for further 
culture procedures and blastocyst injection. This selection is essential to increase the 
chance of pluripotency of the ES cell clones. Furthermore, the myeloid leukaemia 
inhibitory factor (LIF) was supplemented to the culture medium to prevent the 
differentiation of ES cells. 
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5.6 Transfection of ES cells 
 
The transfection of ES cells was done by electroporation of 1*107 cells with 50 to 100 µg 
highly pure and linearized targeting vector in electroporation buffer (20 mM HEPES, 137 
mM NaCl, 5 mM KCl, 0,7 mM Na2HPO4, 6 mM Dextrose). Two parallel procedures were 
tested and gave similar results: 
1) a single pulse protocol with 250 V and 500 µF 
2) a double pulse protocol with 800 V / 3 µF followed by 250 V / 500 µF 
Directly after the electroporation, the ES cells were incubated on ice for 5 minutes and 5 x 
105 cells/cm2 were seeded on prewarmed culture plates in co-culture with a feeder cells. 
After 2 days in culture G418 (200-250 µg/ml) was added to the culture medium to select 
for neomycin resistant clones. ES cell clones were picked after 5-7 days in culture. 
 
 
5.7 Maintenance of ES cell clones 
 
ES cells which have undergone homologous recombination were stored in liquid nitrogen 
tanks for more than one year. Approximately 1*106 ES cells were completely resuspended 
in fresh ES cell culture medium and mixed with 1 volume of freeze medium (50 % FCS 
(ES qualified), 40 % ES cell medium, 10 % DMSO). The tubes were overlaid with 
mineral oil and slowly frozen to –80 °C overnight. The following day the tubes were 
placed into the liquid nitrogen tank. 
 
 
5.8 Blastocyst injection 
 
Homologously recombined ES cells were identified by Southern blot analysis and PCR. 
To generate chimeric offspring, 10 to 12 ES cells were injected into pre-implantation 
blastocysts of C57BL/6J mice and transferred to a host mother. The injections were done 
in cooperation with Dr. M. Bösl. 
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 Results 
 
 
 
The results section is divided into two independent, however thematically related parts. 
The first results section describes the full length cloning, analysis of mRNA and protein 
expression, and functional characterization of a novel tenascin family member, designated 
tenascin-N (see pages 40-62). 
The second part of the results describes the construction and analysis of a mouse line 
conditionally deficient in tenascin-R (TN-R) expression. (see pages 63-77). 
 
 
 
1 Tenascin-N: characterization of a novel member of the 
tenascin family  
 
 
1.1 Identification and cloning of TN-N, a novel member of the tenascin 
family 
 
Mouse Expressed Sequence Tags (EST) databases were screened with TN-R, TN-C, and 
TN-W cDNA sequences to detect EST clones displaying significant homology with 
members of the tenascin family. A set of promising ESTs was identified and one of them 
(W29478) was available from a clone collection. The clone was sequenced to determine 
the complete insert size and sequence. The deduced amino acid sequence of the 
approximately 1 kb cDNA insert was analyzed with appropriate structure prediction 
programs and revealed EGF and FN III domains. The cDNA sequence of the putative new 
tenascin gene was extended by PCR using a primer corresponding to the already 
characterized clone W29478 and a second primer derived from sequences of other ESTs 
that showed homology to tenascins (Fig. 3). One combination yielded a PCR product of 
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4039 bps that was cloned and sequenced. Finally, the missing 5‘ and 3‘ ends of the cDNA 
were obtained by RACE experiments. 
 
 
 
Fig. 3: Identification and cloning of TN-N. Two EST sequences (EST1: W29478; EST2: 
W35807) are depicted in their relative position to the full length TN-N sequence. RT-PCR 
experiments with two primer combinations derived from these ESTs resulted in a 4000 bp 
and 4200 bp band, whereas other primers gave unspecific DNA amplifications. The 
missing 5’ (1300 bp) and 3’ (1500 bp) ends of the TN-N sequence were cloned by 5’-
RLM-RACE and 3’RACE, respectively. 
 
 
 
3‘RACE amplified a 1500 bps fragment including the polyA tail and 5’RACE gave rise to 
a 1300 bps fragment containing the putative start codon and almost 100 nucleotides of 5‘ 
UTR (Fig. 3). 
The combined sequence of the cloned EST insert, RT-PCR and RACE products comprised 
a total of 5773 bps (Fig. 4). To exclude the possibility that the combined sequence was 
artefactual, we designed primers to amplify the entire coding region in a single PCR 
experiment and cloned the respective 4.7 kb fragment to confirm its identity with the 
assembled sequence (data not shown). The open reading frame of the TN-N cDNA 
consists of 4683 bps (Fig. 4). The ATG start codon (nucleotides 95-97) is flanked by 
nucleotides resembling the eukaryotic translation initiation signal (Kozak, 1991). In 
1.5 kb
1.5 kb
3` RACE:RT-PCR:
4.2 kb
4.2 kb
4.0 kb
full length sequence of TN-N
5‘ 3‘
EST 1 EST 2
adaptor primer
5‘-RLM-RACE:
1.3 kb
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addition, an in frame stop codon upstream of the ATG suggests that the full length 5’ end 
has been cloned.  
 
 
 
AGTACCAGGACCAGCTCACAGGAGGCAGGGGGATTGGAAGTGGTGCCCAGCAGCCTCCCAGGCCTCCTGGAGTGTCTGATCCCTTTCTCCAAGAATGGGTCTCTGGGGGATGCTCGCCTTCCCCCTGGGATTTCTGCTTGCTTCTGTGCT 150   
                                                                                               M  G  L  W  G  M  L  A  F  P  L  G  F  L  L  A  S  V  L  
 
CCTGGTGGCTTCGGCCCCAGCCACTCCAGAGTCTCCCGGCTGCAGCAACAAAGAGCAACAGGTCACTGTTAGCCACACCTACAAGATTGACGTGCCCAAGTCTGCTCTGGTTCAAGTAGAGACCGACCCACAGTCACTCAGCGATGATGG 300   
  L  V  A  S  A  P  A  T  P  E  S  P  G  C  S  N  K  E  Q  Q  V  T  V  S  H  T  Y  K  I  D  V  P  K  S  A  L  V  Q  V  E  T  D  P  Q  S  L  S  D  D  G  
 
GACATCACTCTTGGCTCCCGGGGAGGATGGGGAGGAGCAGAACATTATCTTCAGGCACAACATCCGTCTTCAGACACCGCAGAAGAATTGCGACCTGGCAGACAGTGTCCAGGACCTGCTAGCCCGGATGAAAAAGCTGGAGGAAGAGAT 450   
  T  S  L  L  A  P  G  E  D  G  E  E  Q  N  I  I  F  R  H  N  I  R  L  Q  T  P  Q  K  N  C  D  L  A  D  S  V  Q  D  L  L  A  R  M  K  K  L  E  E  E  M  
 
GGCAGAGCTGAAGGAGCAGTGCAATACCAACCGCTGCTGCCAGGGGGCTGCTGATCTGAGCCGTCACTGCAGTGGCCACGGGACCTTCCTCCCTGAGACCTGCAGCTGCCACTGTGACCAGGGCTGGGAGGGCGCAGACTGTGATCAGCC 600   
  A  E  L  K  E  Q  C  N  T  N  R  C  C  Q  G  A  A  D  L  S  R  H  C  S  G  H  G  T  F  L  P  E  T  C  S  C  H  C  D  Q  G  W  E  G  A  D  C  D  Q  P  
 
CACCTGTCCTGGGGCTTGCAACGGCCACGGGCGCTGTGTGGATGGGCAGTGCGTGTGTGACGCGCCCTATGTGGGGGTCGACTGCGCCTACGCCGCCTGTCCCCAGGACTGCAGTGGGCATGGCGTGTGCGTGCAGGGTGTCTGCCAGTG 750   
  T  C  P  G  A  C  N  G  H  G  R  C  V  D  G  Q  C  V  C  D  A  P  Y  V  G  V  D  C  A  Y  A  A  C  P  Q  D  C  S  G  H  G  V  C  V  Q  G  V  C  Q  C  
 
CCACGAGGACTTCACAGCAGAGGACTGCAGCGAGCAGCGCTGTCCTGGCGACTGTAGTGGCAATGGTTTCTGTGACACTGGCGAGTGTTACTGTGAGATGGGCTTTACTGGCCCCGACTGTTCCCAGGTGGTGGCTCCTCAGGGCCTGCA 900   
  H  E  D  F  T  A  E  D  C  S  E  Q  R  C  P  G  D  C  S  G  N  G  F  C  D  T  G  E  C  Y  C  E  M  G  F  T  G  P  D  C  S  Q  V  V  A  P  Q  G  L  Q  
 
GTTGCTCAAGAGCACGGAGAACTCTCTGCTGGTGAGTTGGGAGCCCTCCAGTGAGGTAGACTACTACCTGCTCAGCTACTACCCCCTGGGGAAGGAGCAAGCTACAAAACAGGTCCGGGTACCCAAGGAGCAGCACACCTATGACATCAC 1050  
  L  L  K  S  T  E  N  S  L  L  V  S  W  E  P  S  S  E  V  D  Y  Y  L  L  S  Y  Y  P  L  G  K  E  Q  A  T  K  Q  V  R  V  P  K  E  Q  H  T  Y  D  I  T  
 
CGGCTTGCTGCCTGGAACCAAGTACATAGTCACCCTGCGCAACGTGAAGAAAGACATTTCCAGCAGCCCTCAGCATCTACTTGCCACCACAGATCTTGCTGTGGTGGGCACAGCCTGGGTAAATGAAGAGACTGAGACATCCCTCGATGT 1200  
  G  L  L  P  G  T  K  Y  I  V  T  L  R  N  V  K  K  D  I  S  S  S  P  Q  H  L  L  A  T  T  D  L  A  V  V  G  T  A  W  V  N  E  E  T  E  T  S  L  D  V  
 
GGAGTGGGAGAACCCTCTGACTGAGGTGGACTATTACAAGCTTCGGTATGGCCCCTTAACAGGGCAGGAGGTGACAGAGGTCACTGTGCCCAAGAGCCGTGATCCCAAGAGCAGATATGACATCACTGGTCTGCAGCCTGGAACGGAATA 1350  
  E  W  E  N  P  L  T  E  V  D  Y  Y  K  L  R  Y  G  P  L  T  G  Q  E  V  T  E  V  T  V  P  K  S  R  D  P  K  S  R  Y  D  I  T  G  L  Q  P  G  T  E  Y  
 
TAAAATCACAGTTGTGCCCATCCGAGGTGATCTGGAGGGAAAGCCGATTCTCCTGAATGGCAGGACAGAAATTGATGGACCAACCAATGTGGTCACAAATCAGGTGACAGAAGACACAGCATCTGTTTCCTGGGATCCAGTGAGGGCTGA 1500  
  K  I  T  V  V  P  I  R  G  D  L  E  G  K  P  I  L  L  N  G  R  T  E  I  D  G  P  T  N  V  V  T  N  Q  V  T  E  D  T  A  S  V  S  W  D  P  V  R  A  D  
 
CATAGACAAGTATGTGGTGCGCTATATCGCCCCTGATGGGGAGACCAAGGAGAAGGCAGTACCAAAGGACCAGAGCAGCACCGTTCTCACAGGCCTGAAGCCAGGAGAGGCCTACAAAGTCTTTGTGTGGGCTGAGAGGGGCAACCAAGG 1650  
  I  D  K  Y  V  V  R  Y  I  A  P  D  G  E  T  K  E  K  A  V  P  K  D  Q  S  S  T  V  L  T  G  L  K  P  G  E  A  Y  K  V  F  V  W  A  E  R  G  N  Q  G  
 
CAGCAAGAAAGCAGACACCAAGGCCCTCACAGAAATTGACAGTCCAGAAAACCTGGTGACTGACCGGGTGACAGAGAACAGCCTCTCTGTCTCGTGGGACCCAGTGGAGGCTGACATCGACAGGTACGTGGTAAGCTACACTTCCGTGGA 1800  
  S  K  K  A  D  T  K  A  L  T  E  I  D  S  P  E  N  L  V  T  D  R  V  T  E  N  S  L  S  V  S  W  D  P  V  E  A  D  I  D  R  Y  V  V  S  Y  T  S  V  D  
 
TGGAGAGACGAAGCAGGTTCCAGTGAAGAAGGACCAGAGGAGCACCGTCCTCACCGGCCTGAGTCCCGGTGTGGAGTACAAAGTTTACGTGTGGGCAGAGAAAGGCGATCGGGAGAGCAAGAAGGCCAACACCAAGGCTCCCACAGACAT 1950  
  G  E  T  K  Q  V  P  V  K  K  D  Q  R  S  T  V  L  T  G  L  S  P  G  V  E  Y  K  V  Y  V  W  A  E  K  G  D  R  E  S  K  K  A  N  T  K  A  P  T  D  I  
 
CGACAGCCCCAAAAACTTGGTAACTGACCAGGTGACAGAGAACACTCTCAGTGTCTCCTGGGACCCTGTTCAGGCCAACATTGACAGGTATATGGTGAGCTACACCTCTGCCGATGGAGAGACAAGAGAGGTCCCAGTGCCTAAGGAGAA 2100  
  D  S  P  K  N  L  V  T  D  Q  V  T  E  N  T  L  S  V  S  W  D  P  V  Q  A  N  I  D  R  Y  M  V  S  Y  T  S  A  D  G  E  T  R  E  V  P  V  P  K  E  K  
 
GAGCAGTACCGTCCTGACTGGCCTGAGGCCAGGTGTGGAGTACAAGGTCCATGTGTGGGCCCAGAAGGGGACCCAGGAGAGCAGAAAGGCCAACACCAAGGCCCCCACAGATATTGATGGCCCCAAAAACCTGGTGACTGACCAGGTGAC 2250  
  S  S  T  V  L  T  G  L  R  P  G  V  E  Y  K  V  H  V  W  A  Q  K  G  T  Q  E  S  R  K  A  N  T  K  A  P  T  D  I  D  G  P  K  N  L  V  T  D  Q  V  T  
 
CGAGACCACTCTTAGTGTCTCCTGGGACCCAGTGGAGGCTGACATTGATAGGTACATGGTTCGCTACACGTCTCCTGATGGAGAGACCAAGGAGGTGCCTGTGTCAAAGGATAAGAGCAGCACAGTCCTGAGGGGCCTGAGGCCAGGTGT 2400  
  E  T  T  L  S  V  S  W  D  P  V  E  A  D  I  D  R  Y  M  V  R  Y  T  S  P  D  G  E  T  K  E  V  P  V  S  K  D  K  S  S  T  V  L  R  G  L  R  P  G  V  
 
GGAGTACAAGGTGGATGTATGGGCCCAGAAGGGGGCCCAGGACAGCCGGAAGGCCAACACCAAGGCCCCCACAGATATTGACAGCCCTAAAAACCTGGTGACTGAGCAGGTGACAGAGAGCACTGCCACCGTGTCCTGGGACCCAGTAGA 2550  
  E  Y  K  V  D  V  W  A  Q  K  G  A  Q  D  S  R  K  A  N  T  K  A  P  T  D  I  D  S  P  K  N  L  V  T  E  Q  V  T  E  S  T  A  T  V  S  W  D  P  V  E  
 
GGCTGACATCGACAGGTATGTGGTGCGCTACACTTCTGTCGATGGCGAGACCAGGGAATTTCTCGTTGGGAAGGACCAAACAAGCACCGTCCTGACAGGCATGAGACCAGGTGTGGAGTATCAGGTCGACGTGTGGGCCCAGAAGGGGAC 2700  
  A  D  I  D  R  Y  V  V  R  Y  T  S  V  D  G  E  T  R  E  F  L  V  G  K  D  Q  T  S  T  V  L  T  G  M  R  P  G  V  E  Y  Q  V  D  V  W  A  Q  K  G  T  
 
ACAGGAAAGCAGGAAGACCAGCACCAAAGCCCCAACAGATATTGATGGCCCCAAAAACCTGGTGACTGACCAGGTGACCGAGACCACTCTTAGTGTCTCCTGGGACCCAGTGGAGGCTGACATTGATAGGTACATGGTTCGCTACACGTC 2850  
  Q  E  S  R  K  T  S  T  K  A  P  T  D  I  D  G  P  K  N  L  V  T  D  Q  V  T  E  T  T  L  S  V  S  W  D  P  V  E  A  D  I  D  R  Y  M  V  R  Y  T  S  
 
TCCTGATGGAGAGACCAAGGAGGTGCCTGTGTCAAAGGATAAGAGCAGCACAGTCCTGAGGGGCCTGAGGCCAGGTGTGGAGTACAAGGTGGATGTATGGGCCCAGAAGGGGGCCCAGGACAGCCGGAAGGCCAACACCAAGGCCCCCAC 3000  
  P  D  G  E  T  K  E  V  P  V  S  K  D  K  S  S  T  V  L  R  G  L  R  P  G  V  E  Y  K  V  D  V  W  A  Q  K  G  A  Q  D  S  R  K  A  N  T  K  A  P  T  
 
AGATATTGATAGTCCCAAAAACCTGGCGATCGACCAGGTGACAGAGACCACTCTCAGTGTCTCCTGGGACCCAGTACAGGCTGACATTGACAGGTATGTGGTGCGCTACACCTCTGCTGATGGGGAATCCAAAGAATTCCTGATTGGGAA 3150  
  D  I  D  S  P  K  N  L  A  I  D  Q  V  T  E  T  T  L  S  V  S  W  D  P  V  Q  A  D  I  D  R  Y  V  V  R  Y  T  S  A  D  G  E  S  K  E  F  L  I  G  K  
 
GGAACAGAGGAGCACAGTCCTGACAGGCCTGAGGCCAGGTGTGGAGTACAAGGTTGAAGTGTGGGCCCAGAAAGGAGCCCGGGAGAGCAAGAAAGCCAACACCGAAGGTCACACAGACATTGACAGCCCCAAAAACCTGGTGACCAATCA 3300  
  E  Q  R  S  T  V  L  T  G  L  R  P  G  V  E  Y  K  V  E  V  W  A  Q  K  G  A  R  E  S  K  K  A  N  T  E  G  H  T  D  I  D  S  P  K  N  L  V  T  N  Q  
 
GGTGACCGAAAATACAGCCACCATCTCCTGGGACCCGGTGCAGGCTGATATTGACAGATACATGGTGCGCTACACATCTGCTGATGGAGAGACCAGGGAGATTCCAGTGAGGAAGGAGAAGAGCAGCACTGTCCTCACAGGCCTGAGACC 3450  
  V  T  E  N  T  A  T  I  S  W  D  P  V  Q  A  D  I  D  R  Y  M  V  R  Y  T  S  A  D  G  E  T  R  E  I  P  V  R  K  E  K  S  S  T  V  L  T  G  L  R  P  
 
GGGTGTGGAGTACACGGTCCAAGTGTGGGCTCAGAAGGGGGCCCGGGAGAGCAAGAAGGCCAAAACCAAGGCCCCCACAGAAATTGACAGCCCCAAGAACTTGGTGACCAACCGAGTGACAGAAAATACAGCCACCATCTCCTGGGACCC 3600  
  G  V  E  Y  T  V  Q  V  W  A  Q  K  G  A  R  E  S  K  K  A  K  T  K  A  P  T  E  I  D  S  P  K  N  L  V  T  N  R  V  T  E  N  T  A  T  I  S  W  D  P  
 
AGTGCGAGCCAACATTGACAGGTACATGGTTCGCTACACCTCTGCGGATGGAGAGACTAAGGAGATTCCAGTGTCAAAGGATCAGAGTAGCACCATCCTGACAGGCCTGAAACCAGGCATGGAATATACCATTCATGTGTGGGCCCAGAA 3750  
  V  R  A  N  I  D  R  Y  M  V  R  Y  T  S  A  D  G  E  T  K  E  I  P  V  S  K  D  Q  S  S  T  I  L  T  G  L  K  P  G  M  E  Y  T  I  H  V  W  A  Q  K  
 
GGGGCCCCGGGAGAGCAAGAAGGCTGATACCAAGGCCCTAACAGAAATTGACCCTCCCAGAAATCTCCGTCCGTTCGGGGTAACACATTCTGGTGGGGTTTTGACCTGGTTGCCCCCATCTGCTCAAATTGATGGCTACATTTTGACCTA 3900  
  G  P  R  E  S  K  K  A  D  T  K  A  L  T  E  I  D  P  P  R  N  L  R  P  F  G  V  T  H  S  G  G  V  L  T  W  L  P  P  S  A  Q  I  D  G  Y  I  L  T  Y  
 
CCAGTTCCCAAATGGCACCGTGAAGGAGGTGGAGCTCCCAAGAGGCCAGCAGAGATTTGAATTGCAAGACCTGGAACAGGGTGTCACCTATCCTGTTTCCTTGGTTGCCTTCAAAGGTAATCAGCGGAGCCGGACTGTGTCTACCACCCT 4050  
  Q  F  P  N  G  T  V  K  E  V  E  L  P  R  G  Q  Q  R  F  E  L  Q  D  L  E  Q  G  V  T  Y  P  V  S  L  V  A  F  K  G  N  Q  R  S  R  T  V  S  T  T  L  
 
TTCTACAGTGGATGCTCGCTTTCCACACCCCTCAGACTGCAGTCAAGTTCAGCAGAACACCAACGCTGCCAGTGGGCTCTACACCATCTACCTCAATGGTGATGCCAGCCGGCCCATGCAGGTGTACTGCGACATGGACACCGACGGAGG 4200  
  S  T  V  D  A  R  F  P  H  P  S  D  C  S  Q  V  Q  Q  N  T  N  A  A  S  G  L  Y  T  I  Y  L  N  G  D  A  S  R  P  M  Q  V  Y  C  D  M  D  T  D  G  G  
 
CGGCTGGATTGTCTTCCAGAGACGGAACACTGGGCAGCTGGATTTCTTCAAGCGTTGGCGGAGTTATGTAGAAGGTTTTGGGGACCCCATGAAGGAGTTCTGGCTTGGACTTGATAAACTACATAATCTCACCACTGGCACCACCACTCG 4350  
  G  W  I  V  F  Q  R  R  N  T  G  Q  L  D  F  F  K  R  W  R  S  Y  V  E  G  F  G  D  P  M  K  E  F  W  L  G  L  D  K  L  H  N  L  T  T  G  T  T  T  R  
 
GTATGAGGTGAGGGCAGACTTACAGACTTTCAATGAATCTGCCTACGCTGTATATGATTTCTTCCAAGTGGCATCCAGCAAAGAGCGGTACAAGCTGTCGGTTGGGAAATACAGAGGCACAGCCGGGGATGCTCTCACCTACCACAATGG 4500  
  Y  E  V  R  A  D  L  Q  T  F  N  E  S  A  Y  A  V  Y  D  F  F  Q  V  A  S  S  K  E  R  Y  K  L  S  V  G  K  Y  R  G  T  A  G  D  A  L  T  Y  H  N  G  
 
ATGGAAGTTCACGACTTTTGACAGAGACAATGATATTGCCCTCAGCAACTGTGCACTGACGCATCATGGTGGCTGGTGGTATAAGAACTGCCATTTGGCCAACCCGAATGGCAAATATGGGGAGACCAAGCACAGCGAGGGGGTGAACTG 4650  
  W  K  F  T  T  F  D  R  D  N  D  I  A  L  S  N  C  A  L  T  H  H  G  G  W  W  Y  K  N  C  H  L  A  N  P  N  G  K  Y  G  E  T  K  H  S  E  G  V  N  W  
 
GGAGCCATGGAAGGGACATGAGTTCTCCATTCCTTATGTGGAGCTGAAAATCCGCCCGTTTGGTTACAGCAGAGACCGTTTCTCTGGCAGAAAGAAGCGCTCCATAGGAAAAGCAAGGATGTTCTGAAGGCTTGTCTGAGCTGTCTTCAC 4800  
  E  P  W  K  G  H  E  F  S  I  P  Y  V  E  L  K  I  R  P  F  G  Y  S  R  D  R  F  S  G  R  K  K  R  S  I  G  K  A  R  M  F 
 
AGGAGACAAGAGAAACTTGGGGTTGGCGGGGTAGATGGTGCCTAGGAAGCTGAAGTTTGAGGGATGCTCATAGCCTCCGACTTCCTAGATTGCTGGGTACACAGTGCTAATGACGTCATCACACTTTGACCTTTAGAGGTTCCTTCCATG 4950  
TCATCTGCAAGTTTGACTGTCTCTACTGAGGGCTTCATTGTTGGCTTTCAGGAGCCAACAATGTTGTAACTGAACAGTACATATGGATAGAACACGTGTTGGAATCACAAGGTTTTTTCAGCCCATCCTTAATGACAGATGTATTGAATT 5100  
AGGGCAAAAAGGTGAACCATCCTGTAGACCATCAATTGGAAATCTTTAGAAATTGGTGGAGATCTCTGTATCCATCTGATAATATAGATCTTTGTAGAAAAAAAAAGACAAAGTGAGGTTCTGATCCCCTGGGTGTCAGAGCTGAGGCGA 5250  
CCTGCTACTTCTTGTCTCTCCTGGACCTCCTGGTGTTTGAAGGAAATGTTTATATCTTACTACTTTTAAACTTCCTGTGTGATGAAGAATGAAGAGACTACAAAGGGGCCACGATGCAGTCATAGTTAAGTTCTGACTAGTCTCTAGCAT 5400  
TCTAGAGACCAAAGCTCCCATTTTATTGCTATTTTTAACTGCCCCTTTTCCAGACATTTGCATAAGTTCTTTCATAGATCTGCATATGTTGTAAATAAATTTGCAGTCATTTAAACTTTAAATAACCCATCTCTTTAAATAACTGGTCCC 5550  
CTCAGCTCCCCCCCACCACTTCACTCACCTCCATGCCTCTCCCCTCCCCCGGGTCCATCAGCCCTCAGACTCCCTCCTTCCCTGCTCCCCACACTGGAAGCTTCCTCACATCATCTTTCTTGCGTGTTTGGTGTCATTTTGGAAAGTTTT 5700  
CTGTAACCAAGTCAGTGACCTTTGAAGTAACTTAAATTCCTACTCAAGAAAACACAAATAAACTGTTTGATTT                                                                              5773 
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Fig. 4: The cDNA and deduced amino acid sequence of the murine TN-N gene. The 
open reading frame is preceded by an in-frame stop codon (printed in bold letters). 
Specific domains and features of the protein are indicated: The hydrophobic signal 
sequence predicted by the van Heijne method (von Heijne, 1986) is underlined, and 
conserved cysteine residues at the amino-terminal cysteine-rich region are marked with 
asterisks; arrows indicate the start of modular domains, which are epidermal growth 
factor-like domains (EGF 0.5 to 3), fibronectin type III-like domains (FNIII 1 to 12), and a 
globular domain homologous to fibrinogen (FBG). The RGD motif located in domain 
FNIII 2 and the TGA stop codon of the open reading frame are printed in bold and 
underlined. The sequence data have been deposited in GenBank/EMBL/DDBJ under the 
accession number AF455756. 
 
 
 
The TN-N open reading frame is terminated by a TGA stop codon (nucleotides 4775-
4777) shortly after the region coding for FBG (Fig. 4).The 3’ UTR contains a 
polyadenylation signal (AATAAA) at position 5757-5762 bp, indicating that the clone 
covers the complete 3’ end of TN-N. The 5’ and 3’ UTR are 94 bp and 993 bp in length, 
respectively.  
 
 
 
1.2 Analysis of the protein structure of TN-N 
 
The protein encoded by the TN-N mRNA comprises 1560 amino acid residues with a 
calculated molecular mass of 173 kD. From the deduced amino acid sequence, a number 
of protein domains can be predicted. The 23 amino-terminal residues constitute a 
hydrophobic region (Fig. 4) which is predicted to be a signal peptide with a putative 
cleavage site at position 23 according to McGeoch's algorithm and von Heijne's method 
(McGeoch, 1985; Nakai and Kanehisa, 1991; von Heijne, 1986). Thus, amino acid 24 is 
likely to be the first residue in the processed protein. Similar signal peptides have been 
described for TN-R (Fuss et al., 1993) and TN-W (Weber et al., 1998) and can also be 
predicted for TN-C with the algorithms mentioned above. 
The amino-terminus of the mature protein consists of a cysteine-rich segment of 131 
residues that contains 7 cysteine residues at conserved positions when compared to TN-C, 
TN-R, and TN-W (Jones et al., 1989; Fuss et al., 1993; Weber et al., 1998). The region of 
the EGF repeats begins with a single incomplete EGF domain of 16 residues followed by 
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3 complete EGF domains with a length of 31 residues each. Twelve FN III domains are 
positioned carboxy-terminally of the EGF repeats, and a FBG domain is present at the 
carboxy-terminus of the TN-N protein (Fig. 4). All of these modular elements are found in 
other tenascin family members (Fig. 5) (for review see: Jones and Jones, 2000). 
Nine out of the 12 FN III domains in TN-N show homologies of approximately 70 % and 
thus are significantly more related to one another than to FN III domains of other 
tenascins. A special feature of TN-N which is unique among the tenascin family is the 
occurrence of two identical FN III domains at positions 6 and 8 (Table I and Fig. 5). 
 
 
 
 
 
 
Fig. 5: Schematic representation of the domain structure of TN-N compared to 
known tenascins. The depicted modular structure is characteristic for tenascins. All 
tenascin proteins share an amino-terminal cysteine-rich region (curved line), EGF repeats 
(filled rhombi), FNIII domains (rectangles), and a carboxy-terminal FBG domain (oval). 
Similar domains are indicated by numbers, whereas letters denote alternatively spliced 
domains. The identical FN III domains 6 and 8 in TN-N are marked by striped rectangles. 
In TN-X and TN-Y the pentagons symbolize serine and proline rich regions (SPX) that are 
present only in these tenascins.  
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Table I: Sequence homologies of the FN III domains of TN-N 
 
FN III 
domain 1 2 3 4 5 6 7 8 9 10 11 12 
1 100 47 38 42 41 34 32 34 35 34 34 30 
2  100 37 38 37 39 30 39 32 35 33 <30 
3   100 65 65 70 66 70 62 64 65 36 
4    100 76 75 73 75 74 70 70 35 
5     100 83 76 83 77 84 75 36 
6      100 76 100 76 78 71 38 
7       100 76 76 78 71 35 
8        100 76 78 71 38 
9         100 76 67 36 
10          100 83 33 
11           100 33 
12            100 
 
Listed are the percentages of identical amino acid residues between each pair of FN III 
domains of TN-N as determined by the BLAST 2 sequences program. Bold numbers show 
that homologies between FN III domains 3 to 11 are significantly increased compared to 
FN III domains 1, 2, and 12. The underlined value highlights the identity of FN III 
domains 6 and 8.  
 
 
 
1.3 Phylogenetic relationship between TN-N and other tenascins 
 
Comparison of the entire amino acid sequence of the mouse TN-N protein with mouse 
TN-C, rat TN-R, zebrafish TN-W and chicken TN-Y revealed only low homologies to 
these tenascins. The general homology of TN-N domains with those of TN-W is slightly 
higher than the homologies with other tenascins (Table II). This is confirmed by the 
analysis of the ancestral relationship of the tenascins by the Clustal 5 method (Higgins and 
Sharp, 1989). The phylogenetic tree resulting from this analysis is shown in Fig. 6 and 
presents TN-N on a separate branch closer to TN-W than to TN-C and TN-R, whereas 
TN-X and TN-Y seem to be the most distant relatives of TN-N. 
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Fig. 6: Phylogenetic relationship of the tenascin protein family. A phylogenetic tree 
illustrates the ancestral relationship of the tenascin family members. The scale beneath the 
tree measures the phylogenetic distance between sequences, and the units indicate the 
number of substitution events. The tree was generated based on a multiple sequence 
alignment of amino acid sequences using the Clustal 5 method (Higgins and Sharp, 1989). 
 
 
 
In conclusion, TN-N is not an orthologue of any other known tenascin protein. This is 
confirmed by the comparison of the TN-N specific protein domains with those of the other 
tenascin family members (Table II). When subdomains of TN-N are compared to 
corresponding arrays of domains in other tenascins, no striking similarities are found. The 
highest level of similarity regarding the EGF domains is seen with TN-C. In comparison, 
the EGF domains of orthologues of TN-C from mouse and chicken share higher values of 
up to 85% identical and up to 96% similar amino acids (not shown). The homologies of 
the EGF domains of TN-N compared to those of other tenascins are significantly lower 
(Table II). However, sequence similarity of the FN III domains again suggests a closer 
relationship between TN-N and TN-W rather than between TN-N and TN-C or TN-R. 
Finally, the FBG domain of the tenascins is the most conserved domain and the mouse and 
chicken TN-C orthologues show 83 % identical and 94 % similar amino acids in this 
domain. The FBG domains of TN-N and TN-W share only 64 % identical residues (Table 
II). All these data confirm that TN-N is a novel homologue of the tenascin family. 
Furthermore, the number of EGF and FN III domains varies between tenascin molecules, 
but is more or less constant between orthologues if the alternatively spliced FN III 
domains are not taken into account (Erickson, 1993; Chiquet-Ehrismann et al., 1994; 
Erickson, 1994; Chiquet-Ehrismann et al., 1995). Although TN-N displays the same 
number of EGF domains as TN-W, the number of FN III domains is unique among the 
tenascins. 
01020304050607080
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Table II: Amino acid sequence comparison of TN-N domains with TN-C, TN-R, TN-
W, and TN-Y. 
 
TN-N 
domains TN-C TN-R TN-W TN-Y 
Cys.-rich 26 37 33 n.s. 
EGF-1 44-70 48-59 51-62 n.s. 
EGF-2 48-66 48-59 48-55 51 
EGF-3 48-63 44-59 51-59 59 
FN III - 1 28-34 28-35 31-46 27 
FN III - 2 30-39 30-38 35-44 n.s. 
FN III - 3 28-38 32-36 33-52 n.s. 
FN III - 4 25-42 30-38 30-55 26-31 
FN III - 5 23-41 28-38 32-52 24-27 
FN III - 6 25-39 29-39 26-53 24-27 
FN III - 7 22-42 27-37 32-52 22-24 
FN III - 8 25-39 29-39 26-53 24-27 
FN III - 9 23-40 28-37 30-52 24-25 
FN III - 10 25-43 25-38 30-56 24 
FN III - 11 25-43 25-39 30-55 22-24 
FN III - 12 26-38 28-34 36-43 41 
FBG 56 58 64 48 
 
Listed are the percentages of identical amino acids between single TN-N domains and 
protein sequence of a tenascin family member as calculated by the BLAST 2 sequences 
program. A single number indicates only one match between the TN-N domain and the 
respective member of the tenascin family. Where the TN-N domain matched more than 
one region of the tenascin molecules, the lowest and highest values are given. No 
significant similarity is indicated by n.s.. 
 
 
 
1.4 The genomic structure of the human TN-N 
 
The existence of TN-N in other species than mouse was confirmed by BLAST data base 
searches. The complete coding sequence of the mouse TN-N was used to screen for 
homologous sequences in human genomic data bases. Since the human genome has been 
sequenced to completion, it was expected to find a human orthologue to the mouse TN-N. 
The search revealed a highly homologous genomic area at chromosome 1 in position 
q23.3-24.3 with a size of approximately 71000 bp (Fig. 7). The genomic structure is 
composed of 18 exons and 17 introns. The exon structure allowed to deduce a potential 
mRNA sequence which contained a total length of 4750 bp with an open reading frame of 
                                                                                                                                     Results 
48 
3885 bp and thus converted into an 1295 aa protein. From this protein sequence 3.5 EGF 
domains, 9 FN III domains and a single fibrinogen-like sequence could be predicted with 
up to 84 % similar amino acids to the mouse TN-N protein. 
 
 
 
 
 
Fig. 7: Schematic representation of the genomic structure of the putative human TN-
N. The in silico predicted genomic architecture of the human TN-N contains 18 exons (I 
to XVIII) and 17 introns. The deduced mRNA can be predicted from this structure, has a 
total length of 4750 bp, and shows an open reading frame of 3885 bp. 
 
 
 
1.5 Northern blot analysis and discovery of a splice variant of TN-N by 
RT-PCR 
 
The distribution of TN-N specific transcripts was investigated by a mouse multiple tissue 
Northern blot. A 350 bp cDNA probe corresponding to the first and second FN III domain 
of the mouse TN-N was used for hybridization. A mRNA species of approximately 6 kb 
was strongly detected in adult kidney and to a lower extent in adult spleen after overnight 
exposure to film (Fig. 8A). In brain, a hybridization signal was hardly detectable after 
overnight exposure. In a comparable Northern blot analysis of brain tissues a TN-N signal 
could be detected after 5 day exposure (not shown), suggesting a low transcript level 
compared to kidney and spleen. To confirm the Northern blot signal of TN-N in the brain, 
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RT-PCR was performed with adult hippocampal mRNA and primers designed to amplify 
a 2300 bp fragment of the cDNA encoding FN III domains 1 to 10. The RT-PCR yielded 
also a second product of 2000 bp (Fig. 8B), which was cloned and sequenced. It was 
identified as a splice variant of the larger size TN-N cDNA. This shorter isoform lacked 
the region encoding the third FN III domain. 
 
 
 
Fig. 8: Expression profile of TN-N mRNA and detection of an alternatively spliced 
TN-N transcript. (A) The distribution of TN-N specific transcripts was analyzed with a 
multiple tissue Northern blot containing mRNA preparations from heart (h), brain (b), 
spleen (s), lung (lu), liver (li), skeletal muscle (sm), kidney (k), and testis (t). In each lane 
2 µg mRNA was loaded. (B) The amplification of two TN-N specific products obtained by 
RT-PCR of adult hippocampus mRNA (1) demonstrates the presence of two alternatively 
spliced TN-N transcripts. The shorter form lacks the third FN III domain. The size of 
DNA marker fragments (M) is indicated in kb. 
 
 
 
1.6 Immunoblot analysis of TN-N expression 
 
To investigate TN-N expression at the protein level, a polyclonal antibody was generated. 
The TN-N antibody was directed against a peptide which corresponded to the second FN 
III domain of the TN-N protein. Immunoblots of crude tissue extracts from brain and 
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kidney of adult mice detected a protein both in kidney and in brain with a mass of 
approximately 170 kD (Fig. 9A), which is in accordance with the calculated molecular 
weight of TN-N. 
 
 
 
Fig. 9: Characterization of the TN-N antibody and immunoblot detection of the TN-
N protein in several mouse tissues. (A) 50 µg of crude protein extracts from brain (b) 
and kidney (k) were subjected to Western blot analysis using a polyclonal antibody against 
a TN-N derived peptide. Except for the 170 kD band, all other bands obtained with the 
antibody (-) were not related to TN-N, since preincubation of the antibody with 50 µg of 
the TN-N peptide used for immunization (+) did not abolish these signals. (B) Detection 
of TN-N in 50 µg of fractionated proteins from kidney (k), brain (b), liver (l), and spleen 
(s). (C) Fractionated protein extracts (100 µg) of different regions of the brain (ob, 
olfactory bulb; hip, hippocampus; cor, cortex; thal, thalamus; cere, cerebellum; bs, brain 
stem) from 8-day-old and adult mice. 
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The reactivity of the TN-N antibody with two other proteins of higher and lower 
molecular weights could not be eliminated by preincubation of the antibody with the 
peptide used for immunization. This preincubation completely abolished the TN-N 
specific signal at 170 kD, even after prolonged exposure to film (Fig. 9A left and middle 
panel). All non-specific bands and an additional 120 kD protein were also detected with 
the preimmune serum (Fig. 9A, right panel) and could be removed by an additional high 
speed centrifugation step of the crude tissue extracts (Fig. 9B). The immunoblot analysis 
confirmed the Northern blot analysis: strongest TN-N expression was detectable in kidney 
followed by spleen and brain. TN-N expression was also examined in subregions of the 
brain from adult and 8-day-old mice. Highest expression was found in hippocampus, 
cerebellum and olfactory bulb of adult brains, whereas the TN-N protein was generally 
less abundant in 8-day-old mice (Fig. 9C). The most pronounced age difference could be 
observed in the cerebellum. 
 
 
 
1.7 In situ hybridization analysis of the TN-N expression 
 
To investigate the tissues expressing TN-N in more detail, in situ hybridization 
experiments on cryosections of adult kidney, spleen and brain were performed. 
Furthermore, complete embryos of different developmental stages were analyzed.  
 
 
1.7.1 In situ analysis of the mouse kidney 
 
The analysis of hemisected adult kidneys revealed strong expression of TN-N in the outer 
medulla and a weaker one in the inner medulla while the cortical zone remained 
completely negative (Fig. 10A to C). More specifically, in the inner and innermost stripe 
of the outer medullary zone multiple distinct areas with a strong hybridization signal were 
separated by tissue areas with a much weaker silver grain development in the emulsion. 
Microscopic inspection of successive unlabelled frozen sections which were stained with 
hemalum clearly revealed that the heavily labelled areas correspond to tubular structures 
of descending and ascending limbs of long loops of Henle and collecting ducts, while the 
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much weaker labelled areas between them are related to vascular bundles and descending 
limbs of short loops of Henle (Fig. 10C) (Kriz and Koepsell, 1974). The localization of 
autoradiographic hybridization signals to epithelial tubular structures of the outer 
medullary zone was substantiated by hybridization experiments with DIG labelled probes 
(data not shown). First expression of TN-N in the medulla could be detected in postnatal 
day 10 longitudinal murine kidney sections. In postnatal day 7 mice, however, the outer 
medulla is negative for TN-N transcripts. In experiments designed to find differences in 
the expression profiles of the two splice variants, we used a probe that detected all TN-N 
splice variants (the probe coded for the first and second FN III domain) and compared it to 
a probe detecting only the full length TN-N (this probe coded for the third FN III domain 
only). It turned out that there was no obvious difference in the expression profiles of the 
two TN-N isoforms (data not shown). 
 
 
1.7.2 In situ analysis of mouse spleen tissues 
 
In situ hybridization analysis of the adult spleen showed a specific occurrence of TN-N in 
the white pulp (Fig. 10D to F) consisting of lymphoid tissue. Predominantly the 
periarterial lymphatic sheath (PALS) of the white pulp, representing the T-cell-zone, 
showed a spotted expression pattern (Fig. 10F). This spotted pattern suggested a cell type 
specific localization of TN-N transcripts, probably in macrophages or dendritic cells of the 
PALS. Consecutive cryosections were stained with hemalum to detect cell nuclei and 
enabled the identification of lymphocytes and lipopigment-rich macrophages. The latter 
celltype was characterized by the brownish colour after hemalum staining (Fig. 10H). The 
distribution pattern of PALS specific macrophages was similar to the signal detected by 
the 35S labelled probe (Fig. 10G). To confirm this observation we compared the number of 
PALS specific macrophages with the amount of signal spots visible from radioactively 
labelled cryosections and found similar values. We thus conclude that the TN-N mRNA is 
predominantly expressed in resident macrophages of the PALS. In B-cell lymphoid 
follicles, as well as in the splenic red pulp, no signal was detectable. Furthermore, the lack 
of signals in the white pulp at postnatal day 7 (not shown) supports the idea that the TN-N 
expression is associated with a mature and functioning immune system. In comparison to 
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the signal in the kidneys, the overall intensity of the labelling appeared weaker in the 
spleen, which is in accordance with the Northern blot analyzes (Fig. 8A). 
 
 
 
 
Fig. 10: In situ hybridization analysis of TN-N expression in kidney and spleen. 35S 
labelled sense (s - A, D) and antisense (as - B, C, E, F, G) riboprobes were hybridized to 
cryosections of tissues from 3-month-old mice. Sections shown in C, F, G, and H were 
counterstained with hemalum to visualize cell nuclei. In the kidney (A - C) hybridization 
signals are restricted to structures of the outer and inner zone of the medulla. In the spleen 
(D - H) the white pulp shows a strong hybridization signal (E) which can be recognized as 
a dotted pattern in the periarterial lymphatic sheath (PALS) at higher magnification (F). 
                                                                                                                                     Results 
54 
The distribution of silver grains in the PALS (G) corresponds to that of lipid-rich PALS 
macrophages (brownish cells, H). 
 
 
 
 
1.7.3 In situ analysis of prenatal developmental stages of the mouse 
 
The investigation of prenatal stages of mouse development revealed expression  of TN-N 
mRNA in several unrelated anatomical structures. A TN-N specific signal was first 
detected in the developing skeletal system at embryonic day 14 (E14) when densely 
packed silver grains were obviously related to the initial appearance of ossification 
centers. On E16 the vertebral column, thoracal ribs, the clavicles, part of the sternum, the 
diaphyses of long bones such as humerus and femur, mandibular and maxillary primordia, 
primordia of teeth, and the temporal and parietal bone primordia of the skull were strongly 
labelled (Fig. 11A to C). At higher magnification the hybridization product could be 
assigned to either mesenchymal / perichondral tissue surrounding skeletal elements, e.g. 
ribs (Fig. 11D and E), sternum, humerus and vertebral column, or mesenchymal tissue 
structures which subsequently undergo membranous ossification such as maxilla and 
premaxilla as well as os frontale and parietale of the skull. On postnatal day 0 (P0), the 
expression pattern of the skeletal system remained principally unchanged, but at these 
time points the labelling signal was strongly intensified due to the to progression of the 
ossification process. In addition to the predominantly periostal pattern of the earlier stages 
(E14, E16), now more interior parts adjacent to the cortical layer of the diaphyses of long 
bones (Fig. 11H and I), vertebral bodies, and ribs exhibited a clear hybridization signal. 
This signal corresponded to the beginning formation of cancellous bone tissue (Fig 11J). 
Thus, TN-N expression reflects the general progression of ossification irrespective of 
membranous or enchondral modes of bone tissue formation. In addition to the skeletal 
system, a consistent yet less intense hybridization signal was detected at E16 and P0 along 
the intestinal tract including oesophagus and large bowel. Microscopical inspection 
allowed to assign the label to the smooth muscle layer of the intestinal tract, and 
accordingly a comparatively weak labelling was seen along the wall of large blood vessels 
such as the aorta and pulmonary artery. At P0, a further intestinal TN-N localization 
emerged in the apical parts of the now finally differentiating villi of the small intestine 
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presenting a dense silver grain accumulation in the lamina propria beneath the apical 
enterocytes. Apart from these more systemic expression patterns, distinct and localized 
foci with a strong hybridization signal could be observed during the murine fetogenesis in 
the primordia of the upper and lower lips, in the developing nostrils, and at the dorsal 
surface of the tongue (Fig. 11J and K). Here, the hybridization pattern was reminiscent of 
the formation of filiform, fungiform, foliate and vallate papillae of the tongue epithelium. 
Also remarkable was a moderate hybridization signal in the ectoderm of the immature 
cornea of the eye. Perinatally, when cornification of the epidermis starts, a pronounced 
signal appeared in the epidermal stratum spinosum of the skin of the back. 
 
 
 
 
Fig. 11: In situ hybridization analysis of TN-N expression during embryonic 
development. TN-N specific, 35S labelled antisense (as - A, B, E, F, I, J, K) and sense (s - 
C, G) riboprobes were hybridized to cryosections of complete embryos from day 16 (A to 
E) and 19.5 (F to K) post conception. Alizarin red S / toluidine blue O staining was used 
to visualize differentially cartilagnous and osseous tissues (D, H). E16: Sagittal and 
parasagittal sections show strong positive hybridization in skeletal elements of the 
vertebral column, thorax, cranium and extremities (A, B). A strong hybridization signal is 
also present in the region of the oral orificium. A longitudinal section of the oesophagus 
(A) and several cross sections of intestines (A,B) show a less intense hybridization signal. 
Higher magnifications of cross sections of rib primordia (E) demonstrate intensive 
hybridization of perichondrial tissue, while the cartilage rib models remain negative. 
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E19.5: Areas of compact and cancellous bone tissue formation of a sternal sternebrum are 
positively labelled (I). Beside positive labelling of mandibular and maxillary bones, the 
mucosa of the dorsal tongue surface exhibits a distinct hybridization signal (J). Higher 
magnification demonstrate dense accumulations of hybridization label in the connective 
tissue beneath the epithelium of the developing papillae (K).  
 
 
1.7.4 In situ analysis of the mouse brain 
 
In situ hybridization analysis of cryosections of adult mouse brain revealed a distinct 
expression pattern in regions and layers with high neuronal cell density. In frontal sections 
of the forebrain, predominantly the regions rich in neuronal cells, such as cerebral cortex, 
gave strong signals in contrast to the white matter of the corpus callosum (Fig. 12A). This 
observation was confirmed by examination of more posterior sections including the 
hippocampus and part of the midbrain (Fig. 12B) or in sections through the hindbrain with 
cerebellum and medulla oblongata (Fig. 12C). At higher magnifications of the cerebral 
cortex and corpus callosum (Fig. 12I) a predominant occurrence of TN-N transcripts was 
again found in neuronal cell bodies, but not in the white matter of corpus callosum. The 
autoradiographs also revealed pronounced signals in the cerebellum and choroid plexus, 
which was strongly labelled compared to e.g. medulla oblongata. TN-N mRNA was most 
abundant in the Purkinje and granule cell layers and not detectable in the molecular layer 
of the cerebellum (Fig. 12J). The Purkinje and granule cell layers were as intensely 
labelled as the choroid plexus (Fig. 12J and K). The autoradiographs of brain were 
obtained after exposure to film for 4 days, indicating a significantly weaker mRNA level 
of TN-N compared to kidney and spleen for which overnight exposures gave sufficient 
signal intensities. 
 
 
1.8 Immunocytochemical analysis of TN-N expression in neuronal cell 
cultures 
 
The results of in situ hybridization experiments suggested that TN-N transcripts were 
abundant in neuronal cells (Fig. 12A to D). To confirm this observation by in vitro 
investigations, we cultured dissociated hippocampal neurons of newborn mice for 5 to 6 
days and applied the TN-N antibody to visualize the TN-N protein on non-permeabilized 
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neurons by laser scanning microscopy. The TN-N antibody labelled neurons and their 
processes, whereas astrocytes showed only very faint background staining (Fig. 12G and 
H). The specificity of the TN-N antibody was confirmed by negative staining obtained 
with the preimmune serum (Fig. 12E and F). The specific localization of TN-N to cultured 
neurons confirmed the in situ analysis. 
 
 
 
 
Fig. 12: In situ hybridization analysis of brain sections and immunofluorescence 
labelling of hippocampal neurons. 35S labelled TN-N specific antisense (as - A, B, C, I, 
J, K) and sense (s – D, L, M, N) riboprobes were hybridized to frontal cryosections of 3-
month-old mice. Note that the autoradiographic detection (A, B, C) revealed staining in 
layers of the brain which predominantly consist of neurons, e.g. pyriform cortex, 
neocortex, thalamus, and granule cell layer, whereas white matter structures of corpus 
callosum, hippocampus and cerebral peduncles are spared. These observations are 
confirmed by higher magnification of the neocortex and corpus callosum (I), the cereballar 
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cortex including Purkinje cells and granule layer (J), and the choroid plexus (K). Sections 
used for micrographs at higher magnifications were counterstained with hemalum to 
reveal the distribution of neuronal and glial perikarya (I to N). Immunofluorescence 
labelling of dissociated hippocampal neurons were incubated with preimmune serum (E) 
or TN-N antibody (G) and demonstrate specific staining of neurons and their processes. 
The micrographs in F and H represent the phase contrast images corresponding to E and 
G, respectively. 
 
 
 
 
1.9 Production of recombinant TN-N domains 
 
To investigate the functional roles of TN-N and to distinguish possible functional 
differences between the two TN-N isoforms, recombinant protein fragments of TN-N 
were expressed in E.coli. Four different protein fragments of the FN III region were 
produced which surrounded the spliced domain of TN-N, including the FN III domains 2 
to 4, domains 2 + 4 (lacking the spliced domain 3), domain 2 only, and, as a control, 
domains 5-7 (Fig. 13A). The protein fragments carried an amino-terminal 6 x His tag and 
could thus be purified in a single step as soluble proteins (Fig. 13B). The purity of the 
recombinant proteins as judged from densitometric analysis of Coomassie-stained gels 
(Fig. 13B) was at least 97%. The apparent molecular masses visible in Fig. 13 were in 
accordance with the molecular masses calculated from the protein fragment sequences. 
The purified fragments were extensively dialyzed against PBS and concentrated prior to 
application to cell culture experiments. The yield of purified proteins after elution from 
Ni2+-ion coupled agarose, dialysis, and concentration was between 5 and 10 mg/l of 
bacterial culture. The TN-N antibody was used to detect the recombinant protein 
fragments by Western blot analysis (Fig. 13C). The fragments corresponding to FN III 
domains 2 to 4 and 2 + 4 of TN-N showed strong bands of expected sizes. In contrast, 
when the recombinant protein corresponding to FN III 5 to 7 was loaded, no signal was 
obtained (Fig. 13C). Since the antibody was directed against a peptide located within FN 
III domain 2, these experiments demonstrate the specificity of the antibody. Furthermore, 
no degradation products were detected, confirming the integrity of the expressed proteins 
(Fig. 13C). 
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Fig. 13: SDS-PAGE and immunoblot analysis of recombinant TN-N fragments. Four 
TN-N fragments comprising distinct FN III domains were expressed in bacteria: the single 
FN III domain 2 (FN III 2), FN III domains 5, 6 and 7 (FN III 5 to 7), FN III domains 2, 3 
and 4 (FN III 2 to 4), and FN III domains 2 and 4 (FN III 2 + 4). (A) Coomassie stained 
gels loaded with bacterial lysates harvested before (L) and 4 h after IPTG induction (I) of 
protein expression, and with fractions of the induced lysates (insoluble pellet (P); soluble 
supernatant (S)). (B) Purification of 6xHis-tagged fragments from the supernatant 
fractions. Aliquots were taken from the supernatant after incubation with Ni2+-agarose 
beads (S), from two washing steps (W1, W2), and two elution steps (E1, E2), subjected to 
SDS-PAGE, and stained with Coomassie blue. (C) Western blot analysis of the purified 
FN III domain 5 to 7 (1), FN III domain 2 to 4 (2), and FN III domain 2 + 4 (3). Marker 
sizes are shown in kD at the left margin. 
 
 
 
1.10 Inhibition of neurite outgrowth and cell migration at a TN-N substrate 
border 
 
The following assays aimed to elucidate whether the two splice variants of TN-N have 
different functions. Therefore, outgrowing neurites and migrating cells from hippocampal 
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CA3 region explants were exposed to substrate borders of the recombinant protein 
fragments of TN-N (Fig. 13). The CA3 subregion of the hippocampus was prepared from 
newborn mice and oriented around a substrate spot that had been coated with the purified 
TN-N fragments. As a positive control, the amino-terminal fragment of tenascin-C (the 
cysteine-rich segment and all EGF repeats) was used, which had previously been shown to 
repel outgrowing neurites in choice situations (Dorries et al., 1996; Gotz et al., 1996). The 
substrate border was made visible by fluorescence of rhodamine-coupled BSA, which was 
coated in a mixture with the recombinant TN-N fragment (Fig. 14D). When substrates 
contained BSA only, neurites readily crossed the border (Fig. 14B). In contrast, nearly all 
neurites were repelled at the boundary of the region where the amino-terminal fragment of 
TN-C had been coated (Fig. 14A). The shorter splice variant of TN-N showed similar 
effects as TNC and the vast majority of neurites were not able to penetrate into the coated 
area (Fig. 14C). 
 
 
 
Fig. 14: Outgrowing neurites are respelled by the recombinant TN-N fragments 
corresponding to FN III 2 + 4. Explants from the hippocampal CA3 region were 
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positioned close to an area coated with FN III 2 + 4 of TN-N (C) or control proteins. 
Arrows point towards the uncoated regions of the substrate. (A) A recombinant fragment 
comprising the EGF-L domain of TN-C served as a positive control (Dorries et al., 1996). 
(B) Rhodamin-coupled BSA was used as a negative control. The fluorescence image of 
the protein border corresponding to B is shown in D. Outgrowing neurites do not enter the 
area coated with TN-N FN III 2 + 4 (C) or EGF-L of TN-C (A). 
 
 
 
To analyze whether the observed inhibition of neurite outgrowth is specific for the shorter 
splice isoform of TN-N, we analyzed possible inhibitory effects of other FN III 
subfragments of the molecule. In Fig. 15A the CA3 explant was positioned directly 
adjacent to the FN III 2 + 4 substrate border and neurites were able to grow in any 
direction from the explant with exception of the area coated with the shorter splice variant 
fragment. In contrast, a substrate containing the FN III domains 2 to 4, including the 
spliced domain 3 (Fig. 15D), showed no repellent effect on neurites, nor did FN III 2 (Fig. 
10C) and FN III 5 to 7 (Fig. 15B) that were tested as controls. 
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Fig. 15: Repulsion of neurite outgrowth is specific for the smaller isoform of TN-N. 
Neurites growing from explants of the hippocampal CA3 region do not pass the substrate 
border when the TN-N fragment FN III 2 + 4 was coated (A), whereas they entered areas 
coated with fragments FN III 5 to 7 (B), FN III 2 (C), or FN III 2 to 4 (D). 
 
 
 
We then asked whether the fragment lacking the FN III domain 3 of TN-N was repellent 
not only for neurites, but also for migrating cells. The behavior of cells migrating from the 
CA3 explants towards an area coated with the respective protein fragment was therefore 
studied. Cells migrated readily into areas coated with FN III 5 to 7 (Fig. 16A) or FN III 2 
to 4 (Fig. 16B), whereas they hardly entered a substrate containing the fragment 
corresponding to the spliced isoform of TN-N (Fig. 16C). This indicates that the TN-N 
fragment lacking the third FN III domain is a repellent substrate not only for outgrowing 
neurites but also for migrating cells. 
 
 
 
Fig. 16: Effects of recombinant FN III fragments of TN-N on migrating cell bodies. 
Explants from the hippocampal CA3 region were positioned close to an area coated with 
recombinant TN-N fragments. Cells migrate into areas coated with FN III 5 to 7 (A) and 
FN III 2 to 4 (B), but stop at the border of areas coated with FN III 2 + 4 (C). 
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2 Conditional gene targeting of the tenascin-R gene 
 
 
 
Gene targeting has become a powerful and indispensable tool to study gene function in 
vivo and to develop mouse models for biomedical research. The combination with site-
specific recombination systems such as the Cre/loxP system of the bacteriophage P1 or the 
yeast derived FLP/FRT system in conditional gene targeting has further extended the 
power of this technique. 
 
 
2.1 A versatile Neo resistance selection cassette for gene targeting 
experiments 
 
The key step of gene targeting is the modification of the gene of interest via homologous 
recombination in embryonic stem (ES) cells with a gene targeting vector including a 
positive selection cassette to enrich for the rare stably transfected ES cell clones. In 
conditional gene targeting experiments, this selection marker is removed after identifying 
correctly recombined ES cell clones to avoid interference with the endogenous gene 
function. To improve the often poor efficiency of the removal and to reduce the risk of 
unwanted ES cell differentiation, we have designed a Neo resistance selection cassette 
with a tandem arrangement of both the loxP and the FRT recognition sequences at both 
ends. This allows excision of the selection marker by expression of either the Cre or the 
FLP recombinase and helps to overcome the problems arising with only one 
recombination system. Furthermore, a frequently observed problem, when using only the 
Cre/loxP system, is the very low rate of type II recombination products leading to floxed 
alleles after transient expression of Cre recombinase in vitro. Therefore it was decided to 
construct the improved Neo resistance cassette in order to allow the versatile and 
alternative use of either both or one of the Cre/loxP or FLP/FRT recombination system 
depending on the experimental demand. In addition, the cassette was flanked with suitable 
restriction sites that allow the insertion of the long and short arm or the transfer of the 
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cassette to another vector. The vector was termed pJN1 and was applied for conditional 
modification of the tenascin-R (TN-R) gene 
 
 
2.1.1 Construction of the versatile Neo resistance cassette 
 
To construct the plasmid named pJN1, the Neo resistance cassette from the vector pKO 
SelectNeo (Lexicon Genetics) consisting of the neomycin phosphotransferase gene driven 
by the pgk promoter and terminated by the bgh polyA sequence was excised via the 
flanking AscI sites and cloned into the unique AscI site of the plasmid pKO Scrambler-
V901 (Lexicon Genetics). For further steps, a clone with the desired orientation was 
chosen and its sequence integrity was confirmed by sequencing. 
A fragment carrying the tandemly arranged loxP and FRT sequence was generated by a 
standard PCR reaction with a pair of partially overlapping primers that were extended to 
the double stranded DNA (Fig. 17). The two primers were: 1) primer "loxP" which 
contained the loxP sequence (bold), a BglII restriction site (italic) and the overlap with 
primer "FRT" (underlined): (5'-tttAGATCTATAACTTCGTATAATGTATGCTATA 
CGAAGTTATGAAGTTCCTATT-3'); 2) primer "FRT" that contained the FRT sequence 
(bold), SalI and SacII restriction sites (italic) and the overlap with primer "loxP" 
(underlined): (5'-aaaGTCGACCCGCGGGAAGTTCCTATACTTTCTAGAGAATA 
GGAACTTCATAACTTCG-3'). 
The PCR product (Fig. 17) was purified in a gel after digestion with BglII and SalI to be 
cloned in a defined direction in the BglII and XhoI sites 5' of the Neo resistance cassette, 
and was cloned as a BglII-SacII fragment into the BamHI and SacII sites at the 3' site 
respectively (Fig. 18). In the final construct the correct, unidirectional orientation and the 
sequence integrity of the loxP and FRT sites and the central Neo resistance cassette was 
confirmed by sequence analysis. 
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Fig. 17: Generation of the loxP/FRT site by PCR. Two overlapping primers were 
amplified to double stranded DNA (1) and digested with BglII and SalI (2). The digested 
DNA fragments were used to construct the plasmid pJN1. Marker sizes are given in bp. 
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Fig. 18: Construction of plasmid pJN1 with a Neo resistance cassette suitable for 
both Cre mediated and FLP mediated excision. The structure of plasmid pJN1: two 
tandemly arranged loxP/FRT sites are flanking the Neo resistance cassette consisting of 
the neomycin phosphotransferase gene (Neo) driven by the pgk promoter (pgk) and 
terminated by the bgh polyA sequence (bpA). The loxP sequence is symbolized by an 
arrow pointing with its head to the 3' site, the FRT sequence by a circle with a tail pointing 
towards the 3' site. Only relevant restriction sites are shown, single cutters are in bold. 
 
 
 
 
2.2 Construction of the targeting vector to generate a conditional 
knockout of tenascin-R 
 
The key step in a gene targeting experiment is the design and cloning of a targeting vector 
that is used to generate recombinant ES cell clones carrying the desired gene modification. 
The application of site specific recombination systems is increasing the complexity of this 
task and requires extensive handling and manipulation of the ES cells.  
In the first place, a detailed knowledge of the organization of the tenascin-R gene was 
needed to select the sequences used for the targeting vector backbone. Therefore, a 18 kb 
genomic clone was analyzed by systematic restriction endonuclease digestion to identify 
the position and cutting frequency of restriction sites (Fig. 19). The results of this analysis 
were used to plan the targeting vector and equip it with all desired features, like position 
of the Neo resistance gene, orientation of loxP/FRT sites and identification of homologous 
and Cre mediated recombined clones by their restriction fragment length in Southern blot 
analysis. 
The targeting vector backbone was generated by successive ligations of two endonuclease 
digestion fragments from the total genomic clone into a pBlue-KS cloning vector. The 
genomic sequence was first digested with EcoRV, the 5 kb fragment was extracted from 
the gel, and ligated to pBlue-KS. In the next step, a 2.5 kb EcoRV and XhoI fragment 
isolated from a digestion of the genomic clone was ligated to the 3’ end of this 5 kb 
EcoRV fragment (Fig. 19). The cloned part of the TN-R genomic sequence was used as 
the targeting vector backbone. 
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Fig. 19: Genomic organization of the 5’ end of the TN-R gene and generation of the 
targeting vector backbone. A 18 kb genomic ES cell clone containing exons 1 to 3 of 
TN-R was analyzed by systematic restriction endonuclease digestion to identify the 
position and frequency of restriction sites on this clone. The 5 kb EcoRV and the 2.5 kb 
EcoRV/XhoI fragments were cloned into pBlue-KS to generate the targeting vector 
backbone. Abbreviations are: B: BamHI, E: EcoRI, EI: EcoNI, H: HindIII, S: SpeI, SI: 
SacI, V: EcoRV, X: XhoI. 
 
 
 
The targeting vector backbone (Fig. 19) and the plasmid pJN1 (Fig. 18) were used to 
construct the final targeting vector for conditional ablation of the mouse TN-R gene. 
Therefore, the loxP/FRT Neo resistance cassette of the plasmid was excised by HpaI and 
SmaI restriction as a blunt end fragment and inserted into a EcoRV site located within 
intron 1 of the mouse TN-R gene (Fig. 20). A third loxP site was generated by PCR using 
again partially overlapping primers and was equipped with an additional 5' EcoRI site. 
This additional restriction site facilitated the detection in subsequent Southern blot 
analyze. The PCR fragment was flanked by two EcoNI restriction sites for cloning and the 
EcoNI digested fragment was ligated into a single EcoNI site upstream of exon 1 of TN-R 
(Fig. 20). Clones with the correct orientation of loxP were identified by sequence analysis, 
thereby confirming the sequence identity of the newly introduced loxP site. 
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Fig. 20: Cloning steps during the generation of the final targeting vector. A PCR 
fragment containing a single loxP site with an additional EcoRI was ligated 5’ of exon 1. 
Note that the additional EcoRI site is needed to distinguish between recombination events 
by Southern blot analysis. The blunt end fragment obtained by digestion of the pJN1 
plasmid with SmaI and HpaI was ligated to intron1 of the targeting vector backbone. This 
cloning step equipped the targeting vector with a Neo resistance gene flanked by tandemly 
arranged loxP and FRT sites which are suitable for manipulation after homologous 
recombination in ES cells. 
 
 
 
Before the final targeting vector (Fig. 20) was used to mutate ES cells by homologous 
recombination, the functionality of both the loxP/Cre and the FRT/FLP site specific 
recombination was confirmed by Cre or FLP expressing E. coli strains. The strains are 
capable to recombine loxP and FRT sites on exogenous plasmids. The strains 294-Cre and 
294-FLP were kindly provided by F. Steward (Buchholz et al., 1996). The targeting vector 
was transformed into both bacterial strains and 10 clones each were selected for plasmid 
preparation and restriction enzyme analysis. All ten clones showed the site specific 
recombination event, namely the excision of the FRT flanked Neo resistance cassette in 
294-FLP and the deletion of exon 1 plus Neo resistance cassette between the first and the 
third loxP site in 294-Cre (type I deletion). Intermediate excision products between the 
first and second loxP site (type III deletion) or the second and third loxP site (type II) were 
not observed demonstrating that these intermediates are not stable at higher Cre 
expression levels. 
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2.3 Identification of homologously recombined ES cell clones 
 
The ES cell line R1 (Nagy et al., 1993) was cultured on a feeder layer of primary mouse 
embryonic fibroblast cells, which were treated with mitomycin C to block their 
proliferation. ES cells were transfected by electroporation with the linearized targeting 
vector and selected with G418 for the presence of the Neo resistance selection marker. 
Genomic DNA from individual ES cell clones was prepared. For Southern blot analysis 5 
- 10 µg of genomic DNA were digested with EcoRI, electrophoresed and transferred onto 
a nylon membrane. A 500 bp probe was labelled with 32P to detect homologous 
recombination events. In this case, the targeting vector replaced one allele of the TN-R 
gene and the digestion by EcoRI generated two fragments of different sizes. The digestion 
of the wildtype allele generates a fragment that runs at a size of 11 kb, whereas the band of 
the mutated allele has a size of 7.3 kb in Southern blot analysis (Fig. 21 A and B). The 500 
bp probe was derived from intron 2 of the mouse tenascin-R gene located outside of the 
targeting vector at the 3' site (Fig. 21A). 
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Fig. 21: Homologous recombination of the targeting vector with the TN-R gene and 
detection by Southern blot analysis. (A) The targeting vector sequence replaces one 
wildtype allele of the TN-R gene by homologous recombination. Thus, one allele is 
mutated to contain a Neo resistance gene (Neo), loxP and FRT recombination sites (loxP, 
FRT), and an additional EcoRI restriction site. The additional EcoRI site allows to 
distinguish between the homologously recombined allele (mut) and the wildtype allele 
(wt) in southern blot analysis. (B) Southern blot analysis was performed to identify ES cell 
clones which had undergone homologous recombination. The upper panel shows an 
ethidiumbromide staining of the gel electrophoresis of digested genomic ES cell DNA. In 
the lower panel the wildtype band runs at 11 kb, whereas the mutated band is detectable in 
the fourth lane at 7.3 kb. 
 
 
 
In total, 1100 clones were analyzed from two independent transfections of ES cells. From 
these, three different ES cell clones were identified that had undergone homologous 
recombination. Thus, without applying any negative selection markers to counterselect for 
random integration, the targeting frequency was approximately 0.25 %. As estimated from 
the ratio of the band intensity of the mutated vs. the wildtype allele, the three clones were 
90 %, 85% and 60 % pure for homologously recombined cells. 
 
 
2.4 Cre and FLP mediated recombination in ES cells 
 
The Neo selection marker was removed from homologously recombined ES cell clones by 
Cre and FLP mediated recombination. Two homologously recombined ES cell clones 
were subjected to electroporation with plasmid pOG-FLPe (Buchholz et al., 1998) and 
plasmid pPGKcrebpA (Torres and Kühn, 1997) for transient transfection and induction of 
the corresponding site specific recombination system. Transient expression of FLP was 
used to delete the FRT flanked Neo resistance cassette in order to create a floxed allele of 
the tenascin-R gene at exon 1. Clones with the FLP recombined allele were identified by 
their characteristic 5.5 kb EcoRI signal. In parallel experiments, Cre mediated 
recombination in ES cells resulted in type I deletion or type II deletions (Fig. 22 A and B). 
As previously observed, transient expression of Cre recombinase mainly resulted in clones 
with a type I deletion detectable by its characteristic 4.5 kb EcoRI fragment in Southern 
analysis (Fig. 22A and B). Such a clone with a deletion of exon 1 could be used to 
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generate mice with a constitutive inactivation of the tenascin-R gene. Only after extensive 
modulation of transfection conditions and plasmid concentrations, conditions were found 
under which a significant portion of clones exhibited type II Cre recombination with a 
floxed allele identical to the FLP recombination product (Fig. 22). Cre recombinations of 
type III have not been observed. Type II recombinants were used to create a mouse model 
with conditional ablation of TN-R. 
 
 
 
Fig. 22: Cre and FLP mediated recombination in ES cells. (A) Homologous 
recombination of the tenascin-R gene in ES cells. Presented are the mutated allele (mut) 
after homologous recombination and the wildtype allele (wt). These are compared to the 
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recombination products after transient expression of Cre or FLP in ES cells. Either Cre 
recombination of type II or FLP recombination (cre II/FLP) selectively excises the Neo 
resistance cassette leaving the floxed exon 1 and one FRT site in intron 1. Cre 
recombination of type I (cre I) deletes the segment between the first and the third loxP 
site. This removes also exon 1 and creates a constitutive knockout allele. Abbreviations 
are: E: EcoRI, V: EcoRV, X: XhoI. Note, that the figures are not drawn to scale. (B) 
Southern blot detection of site specific recombination events after transient expression of 
the Cre recombinase. Genomic DNA from individual ES clones was restricted with EcoRI 
and hybridized with the radioactively labelled probe. The correctly targeted clone obtained 
by homologous recombination is presented in lane 10 and shows a mutated 7.3 kb band in 
addition to 11 kb wildtype signal. The wildtype fragment is shortened to 7.3 kb in the 
mutated allele by introduction of the additional EcoRI site associated with the 5’ loxP site. 
By excision of the Neo resistance cassette, the mutated fragment is shortened to 5.5 kb 
(cre II / FLP: lane 6) or is converted to 4.5 kb in case of Cre mediated type I deletion (cre 
I). 
 
 
 
 
 
2.5 Generation and breeding of chimeric mice to obtain homozygously 
floxed animals 
 
Two ES cell clones with a floxed TN-R allele were selected for injection into pre-
implantation blastocysts. Ten chimeric mice were born from the transplantation of these 
blastocysts to 3 host mothers. Five-week-old chimeric males were crossed with wildtype 
females to generate heterozygously floxed offspring. Two of six chimeras gave no 
germline transmission. Heterozygously floxed mice were crossbred to generate 
homozygous mice. The genotypes of these mice were characterized by PCR. Therefore, 
primers were designed to bind to the 5’ region of TN-R and to differentiate between 
wildtype, heterozygous, and homozygous genotypes (Fig. 23) 
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Fig. 23: Genotyping of targeted mice. Two primers were deduced from the genomic 
sequence of TN-R to amplify the 5’ part of the gene. The PCR results in a 500 bp band for 
the wildtype animals (2), a double band pattern for heterozygously floxed mice (3), and a 
single 550 bp band for homozygously floxed mice (4). The negative control is shown in 
(1). 
 
 
 
2.6 Conditional gene inactivation of TN-R 
 
TN-R is expressed predominantly by oligodendrocytes of the CNS, but is also produced 
by subpopulations of neurons. It was aimed to generate a mouse model in which TN-R is 
conditionally ablated only from oligodendrocytes of the CNS, thus creating a tissue 
specific and time controlled knockout. 
TN-R was conditionally removed by three different Cre recombinase expressing mice, 
which were crossed with homozygously floxed TN-R animals. The different mouse lines 
were bred until both TN-R alleles were floxed and the Cre transgene was heterozygous 
(TNRFL/FL;Cre) and were compared to homozygously floxed littermates which lacked the 
Cre transgene (TNRFL/FL;WT). 
The transgenic mouse lines that were tested, expressed the Cre recombinase under the 
control of different oligodendrocyte specific promoters: 1) the myelin/oligodendrocyte 
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glycoprotein (MOG) promoter, 2) the proteolipid protein (PLP) promoter, and 3) the 2’,3’-
cyclic nucleotide 3’-phosphodiesterase (CNP) promoter. The activity of these three 
promoters is regulated by the developmental status of the oligodendrocytes. The MOG and 
PLP promoters are predominantly active in mature oligodendrocytes, whereas the CNP 
promoter is also active in oligodendrocyte precursor cells (Nave and Lemke, 1991; Jaquet 
et al., 1999; Berndt et al., 2001; Scherer et al., 1994; Gravel et al., 2000). 
 
 
 
2.6.1 MOG-Cre mediated recombination in floxed TN-R mice 
 
The Cre mediated recombination controlled by the MOG promoter in floxed TN-R mice 
was determined by PCR. Three different primer combinations were used to amplify the 5’ 
part of TN-R, such that the resulting PCR products differ for the floxed allele and the 
recombined allele (Fig. 24). Genomic DNA was prepared from 8 optic nerves taken from 
adult TNRFL/FL;MOG-Cre and TNRFL/FL;WT animals and subjected to PCR. The recombination 
occurred specifically in floxed mice which contained the MOG-Cre transgene, whereas in 
floxed littermates without the Cre transgene, no recombination was detectable by PCR. 
This result was confirmed by three different primer combinations and all showed that the 
floxed TN-R gene had been deleted by the Cre recombinase under the control of the MOG 
promoter (Fig. 24A).  
When Cre recombination occurs at the floxed TN-R locus, the RNA transcribed by the 
mutated TN-R gene is lacking the region encoding the ribosomal binding site, the 
translation initiation codon, the signal sequence, the EGF domains, and the first FN III 
domain (Weber et al., 1999). Thus, the TN-R protein cannot be produced properly by 
oligodendrocytes after the recombination is completed. 
Western blot analysis was performed to determine whether the rather late MOG promoter 
controlled recombination resulted in reduced protein levels of TN-R. Equal protein 
amounts were loaded onto the gel and TN-R was detected by the monoclonal 596 antibody 
directed against the FN III domains 3 to 5 of TN-R. The protein concentration, as 
determined by densitometric measurements of the band intensities, was only slightly 
reduced in the optic nerve and protein preparations of total brain (Fig. 24A and B). A 
maximum of 12 % reduction was measured by this method. 
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Fig. 24: MOG-Cre mediated recombination in floxed TN-R mice. The localization of 
primers used to determine the recombination event is presented in the schematic drawing 
(primer 1 to 4). (A) Optic nerves were analyzed. Three different primer combinations (a, 
b, c) amplified either a single band specific for not recombined alleles of TNRFL/FL;WT (wt) 
animals or an additional smaller band specific for recombination in TNRFL/FL;MOG-Cre 
(trans). In spite of the recombination of the TN-R gene in TNRFL/FL;MOG-Cre mice, the 
Western blot analysis (left panel) detected no reduction of the protein. Protein amounts 
loaded to the gel were controlled by GAPDH. (B) Protein extracts from adult total brain 
showed no reduction in TN-R levels: 1 = TNRWT/FL;WT; 2 = TNRFL/FL;WT; 3 = 
TNRWT/FL;WT; 4 = TNRWT/FL;MOG-Cre; 5 = TNRFL/FL;WT; 6 = TNRFL/FL;MOG-Cre. Note that the 
MOG promoter is active predominately in the mature oligodendrocyte. 
 
 
 
2.6.2 PLP-Cre and CNP-Cre mediated recombination in floxed TN-R mice 
 
The recombination of the floxed TN-R gene mediated by the MOG-Cre transgenic mouse 
line did not result into significant reduction of TN-R protein levels (Fig. 24). Since the 
MOG promoter is predominantly active in mature oligodendrocytes, it was of special 
Exon1 Exon2
loxP  FRTloxP
E
primer2 primer3
MOG-Cre 
recombination
primer1 primer4
floxed TN-R gene
a             b             c
GAPDH
TN-R
1    2      3      4     5     6 
optic nerve optic nerve
total brain
TN-R
w
t
tr
an
s
w
t
tr
an
s
w
t
tr
an
s
w
t
tr
an
s
A B
Exon1 loxP
                                                                                                                                     Results 
76 
interest to analyze other promoters which were active earlier in oligodendrocyte 
development and test them for their ability to reduce the TN-R protein levels. Therefore, a 
PLP-Cre and a CNP-Cre transgenic mouse line were crossed with floxed TN-R mice. 
The conditional ablation of the TN-R gene was tested by PCR with specific primer 
combinations (Fig. 25). The result demonstrated the specific recombination in 
TNRFL/FL;PLP-Cre and TNRFL/FL;CNP-Cre, whereas in wildtype littermates no recombination 
was detectable. 
Protein levels were tested by Western blot analysis using the monoclonal 596 antibody, 
which is directed against the FN III domains 3 to 5 of TN-R. Protein extracts were 
obtained from optic nerves prepared from the respective genotypes. The TN-R protein 
level was not reduced in TNRFL/FL;PLP-Cre compared to TNRFL/FL;WT, but showed a strong 
reduction of 70 % in the TNRFL/FL;CNP-Cre mice (Fig. 25). 
 
 
 
Fig. 25: PLP-Cre and CNP-Cre recombination in optic nerves of floxed TN-R mice. 
The recombination of the floxed TN-R gene leads to a deletion of exon 1 and was 
mediated by two different Cre expressing mouse lines (schematic drawing). The genomic 
recombination occurred specifically in both TNRFL/FL;PLP-Cre and TNRWT/FL;CNP-Cre mice as 
shown by PCR: two primer combinations amplified either a single band specific for not 
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recombined alleles from TNRFL/FL;WT (wt) animals or an additional smaller band specific 
for recombination in TNRFL/FL;PLP-Cre or TNRFL/FL;CNP-Cre (trans). Protein levels were tested 
in Western blot analysis and revealed a strong reduction of TN-R in optic nerves of 
TNRFL/FL;CNP-Cre mice (CNP, trans), whereas in TNRFL/FL;PLP-Cre animals (PLP, trans) the 
protein is not reduced when compared to wildtype littermates. 
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 Discussion 
 
 
 
1 Tenascin-N: characterization of a novel tenascin family 
member 
 
A new member of the tenascin family in mouse (Mus musculus), designated tenascin-N 
(TN-N), was cloned and characterized. The sequence data have been deposited in the 
GenBank/EMBL/DDBJ under the accession number AF455756. At the molecular level, 
TN-N is clearly different from the other tenascins described in mammals, chicken and 
fish. It is composed of a cysteine-rich segment, 3.5 EGF repeats, 12 FN III domains as 
well as a domain homologous to fibrinogen. The second FN III domain contains an 
arginine-glycine-aspartate (RGD) motif. Two isoforms of the molecule generated by 
alternative RNA splicing were also identified. Thus, TN-N is a typical member of the 
tenascin family. 
An interesting feature of the molecule is that two of its FN III repeats are identical, 
suggesting a recent duplication event during evolution. Phylogenetic considerations place 
TN-N of the mouse closest to the structure of TN-W from zebrafish. This makes these two 
proteins less related to TN-C and TN-R which are more closely conserved among each 
other. TN-X and TN-Y are the least related members of the tenascin family with regard to 
TN-N and TN-W on the one hand and TN-C and TN-R on the other. TN-N and TN-W do 
not appear to be species orthologues, since their overall structure is significantly different 
from each other in that TN-W contains only 5 FN III repeats, whereas TN-N contains 12 
of these. Furthermore, the expression profiles of TN-N and TN-W are strikingly different 
from each other and the comparison of subdomain homologies of TN-N with the family 
members confirms that TN-N represents a so far unknown tenascin family member. In 
databases an in silico predicted molecule from human with a similar domain structure as 
TN-N and up to 89 % homology in the FBG domain can be found (accession number: 
AL049689). This demonstrates that orthologues to the mouse TN-N occur in other species 
which have not been characterized yet. Interestingly, the cDNA of this putative human 
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orthologue of TN-N is predicted to contain only 9 FN III domains instead of 12 FN III 
domains as found in the mouse TN-N. The missing FN III domains are probably due to 
differences between the two species. This conclusion is drawn since the analysis of the 
genomic structure of the human TN-N predicted exons coding only for 9 FN III domains. 
Since the analysis was done in silico, it is also possible that additional FN III domains will 
be found when the complete cDNA of the human TN-N is characterized. 
While among the lymphoid organs TN-C expression is maximal in the thymus of 
developing and adult mice (Matsumoto et al., 1994), highest levels of TN-N transcription 
has been detected in the spleen of young adult animals, as shown in this work. TN-N 
expression in the white pulp of the adult spleen exhibits a distinct pattern associated with 
the functionally mature lymphoid tissue. Expression of TN-N mRNA occurs 
predominantly in the periarterial lymphatic sheath (PALS, the T cell zone of the white 
pulp) where the distribution pattern of silver grain accumulations makes TN-N production 
by lymphocytes unlikely, since in this case a diffuse, more homogeneous picture of the 
radioactive label should be expected in the PALS. Rather, the dotted pattern of TN-N 
expression is compatible with the anatomical distribution of resident macrophages in the 
PALS. The splenic localization of TN-N transcripts is clearly different from that of TN-C 
which is associated throughout the white and red pulp of human and murine spleens with 
the extracellular matrix (ECM) of the reticular meshwork formed by developing and 
mature fibroblasts (Liakka and Autio-Harmainen, 1992; Ocklind et al., 1993). It is 
remarkable that the multitude of red pulp macrophages and the specific macrophages of 
the B cell follicles of the white pulp are not labelled by the TN-N probe. The restriction of 
TN-N expression to a subpopulation of mononuclear phagocytes is in line with the well 
established functional and molecular heterogeneity of splenic macrophages (Gordon, 
1998) contributing to the highly compartmentalized organization of this hemolymphoid 
organ and suggests a specific functional role of TN-N producing macrophages in cellular 
immunity. It remains to be investigated whether TN-N is laid down by PALS 
macrophages onto the ECM of the reticular framework of the PALS and thus contributes 
to its specific local microenvironment. 
As in the spleen, strong TN-N mRNA expression in the kidneys becomes evident not 
before morphological and functional maturity during the first 14 postnatal days. TN-N 
expression is confined to the medullary region of the kidneys where transcriptional 
activity can be assigned to epithelial tubular and collecting duct cells. More exactly, TN-N 
mRNA is found in medullary areas where descending and ascending limbs of long loops 
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of Henle and collecting ducts are in close contact with specialized blood vessels. Here, the 
ECM of the interstitial space forms the anatomical basis for the essential water and ion 
exchanges which take place in this part of the nephron during diuresis and antidiuresis. It 
is tempting to speculate that TN-N is deposited together with the TN-C into the interstitial 
ECM of the renal medulla, thus helping to establish a barrier and specific transport 
systems essential for the regulation of water and salt turnover. It is intriguing in this 
context that high TN-N expression, as seen in the epithelial structures of the renal 
medulla, also occurs in the epithelium of the choroid plexuses of the cerebral ventricles. 
The choroid epithelium, although of different histogenetic origin, shares many 
morphological and functional characteristics with the renal tubular epithelium. Similar to 
that of the tubular epithelium for diuresis, its main function is the production of the 
cerebrospinal fluid by selectively excreting water, ions and some other substances into the 
ventricular cavity and simultaneously sustaining a barrier between the perivascular and 
ventricular spaces. It is tempting to speculate that TN-N might interact with ion channels 
as suggested for TN-R and TN-C (Srinivasan et al., 1998). The decrease of conduction 
velocity along the optic nerve in TN-R deficient mice (Weber et al., 1999) and the 
functional modulation of sodium channel beta subunit by TN-R in vitro (Xiao et al., 1999) 
are in agreement with this notion. 
In contrast to TN-N, TN-C is predominantly expressed by mesenchymal cells during early 
embryonic stages of kidney development, e.g. during the initial epithelial/mesenchymal 
interaction in the metanephros anlage and during the fetal stage. In this stage, further 
differentiation of the renal tissues occurs until the formation of nephrons is completed in 
the young adult age. During development TN-C is strongly expressed in both the cortical 
and medullary parts of the kidneys, but in the mature, adult kidneys of mice TN-C like 
TN-N is exclusively expressed in the medulla (Aufderheide et al., 1987; Truong et al., 
1996). TN-C, however, is synthesized by interstitial connective tissue cells while TN-N is 
produced by medullary epithelial cells. At this anatomical site, as in others, the two 
members of the tenascin family may have complementary roles: “mesenchymal” TN-C on 
the one hand acting as an oncofetal ECM glycoprotein with the capacity of being 
reactivated during tumorigenesis, inflammation, and tissue repair, while “epithelial” TN-
N, on the other hand, represents an ECM constituent of functionally mature tissues. 
Since TN-C expression as well as that of other tenascin molecules is more widespread 
during prenatal development than after birth, the studies of the TN-N expression have 
been extended to representative stages of late embryogenesis. In summary, at E16 
                                                                                                                               Discussion 
81 
widespread and strong TN-N-specific in situ hybridization signals were seen in the axial, 
appendicular and cranial skeleton. A less intense presence of TN-N mRNA was also 
observed in the walls of the digestive tract and in large blood vessels. At P0 a strong in 
situ hybridization signal of distinct anatomical sites such as the epithelial connective 
tissues areas of the lips, the dorsal specialized mucosa of the tongue, the epidermis of the 
skin of the back, and the apical regions of the maturing intestinal villi was seen. 
Skeletogenesis is a complex multi phase process regulated over time and TN-C appears to 
be one of the prominent components of the associated skeletal ECM. At an early stage of 
skeletal organogenesis TN-C is involved in the formation of mesenchymal condensations, 
which are regarded as the first structural units of later bones (Hall and Miyake, 2000). 
Thereafter its expression is associated with the differentiation of various cartilaginous, 
osseous and tendinous tissues to be finally down regulated with the exception of a few 
restricted sites when growth and maturation of the organism is completed (Mackie and 
Murphy, 1998). As in the case of spleen and kidneys TN-N transcripts, in contrast to those 
of TN-C, are not detectable during early stages of skeletal development but can readily be 
visualized when the relatively late ossification event of bone development sets in. Similar 
to TN-C, TN-N expression is then predominantly found in the mesenchymal primordia of 
certain cranial bones as well as in the perichondral (to become periostal later) tissue of the 
axial and appendicular skeleton to expand subsequently to regions of bones where typical 
enchondral ossification occurs. Coincident with the progression and extension of 
ossification, an increase in TN-N transcription can be observed irrespective of enchondral 
or membraneous modes of ossification. Importantly and in contrast to reports on TN-C, 
cartilaginous structures do not express TN-N. Summarizing, TN-N and TN-C are 
expressed in the developing skeletal system with unique but partly overlapping spatio-
temporal expression patterns. Whether TN-N disappears from the mature bone matrix as 
does TN-C which only persists in periostal and endostal surfaces (Mackie et al., 1987) or 
more likely is persisting there lifelong remains to be investigated. 
Likewise, systemic TN-N expression in tissue layers of the developing digestive and 
vascular system corresponds to the associated developing smooth musculature. 
Interestingly, TN-C was also reported to appear in the smooth musculature of the 
oesophagus of E15.5 murine embryos but not more caudally in the stomach and the 
intestines where TN-C together with TN-X is localized in the loose connective tissue of 
the lamina propria (Aufderheide and Ekblom, 1988; Matsumoto et al., 1994). 
Colocalization of TN-C with forming smooth muscle of the developing small intestine 
                                                                                                                               Discussion 
82 
was also reported for humans (Beaulieu et al., 1993). Recently, it has been shown that in 
the adult rat TN-C colocalizes with proliferating smooth muscle cells of the aorta and 
pulmonary artery in various experimental settings of vessel wall modelling and 
remodelling (Jones and Rabinovitch, 1996; LaFleur et al., 1997). At present it remains an 
open question whether TN-N represents a permanent component of the differentiated 
vascular smooth musculature or is a temporal and inducible molecule in this tissue, as TN-
C. It is tempting to speculate that prominent occurrence of TN-N in e.g. the developing 
lips, the epithelium of the dorsal tongue surface, or the apical parts of the intestinal villi 
reflects the extensive epithelial-mesenchymal interactions. These are necessary to form 
and sustain such specialized epithelial-connective tissue structures as the different forms 
of glottal papillae or functionally active villi of the small intestine. These morphogenetic 
processes are highly dependent on the elaboration of a specifically adapted ECM. 
Also in the central nervous system, TN-N appears to be spatially and temporally regulated 
and its expression is complementary to TN-C or TN-R. TN-C and TN-R are expressed by 
astrocytes and oligodendrocytes, respectively, whereas TN-N is predominantly expressed 
by neurons. However, TN-R and TN-C are also expressed by certain subpopulations of 
neurons such as horizontal and amacrine cells of the retina, respectively (Bartsch, 1996). 
In the hippocampus, TN-R is expressed by inhibitory interneurons that carry the molecule 
in a particular configuration, the so-called perineuronal nets (Weber et al., 1999 Bruckner 
et al., 2000), whereas TN-C is expressed by granule cells in the adult hippocampus after 
stimulation (Nakic et al., 1998). Thus, some overlap in the expression of TN-N, TN-C, 
and TN-R by neurons is seen, but TN-N is more widely expressed by neurons than TN-R 
and TN-C. Another difference between TN-C and TN-N expression is evident during 
development: Whereas TN-C expression is more predominant at early developmental 
stages, TN-N is more strongly expressed in the adult. 
The question is now which functions TN-N is conveying. First steps towards this analysis 
are presented here, by using an established cell culture system in which TN-C and TN-R 
have been investigated with regard to their ability to promote or inhibit neurite outgrowth 
(Xiao et al., 1996; Dorries et al., 1996; Gotz et al., 1996; Becker et al., 2000). 
Furthermore, the influence of TN-N on neuronal migration was studied. It was of 
particular interest to investigate the functions of the two isoforms of TN-N isolated so far. 
Neurites and migrating neurons of the CA3 region of early postnatal hippocampus were 
confronted with a sharp molecular boundary containing different fragments of TN-N on a 
continuous substrate of a neurite outgrowth and neuronal migration promoting molecule, 
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such as laminin. It could be shown that FN III 3 to 5 and alternatively spliced domains A1 
to A4 of TN-C are repellent for neurite outgrowth in choice situations. It should be 
mentioned as well that the alternatively spliced domains B and D of TN-C enhance neurite 
outgrowth when coated as a homogenous substrate (Gotz et al., 1996). As TN-C and TN-
R, TN-N is repellent for neurites mediated by the FN III domains. Interestingly, the FN III 
domains of TN-N show inhibition of neurite outgrowth and cell migration when the third 
FN III domain is missing in the shorter isoform of the molecule. To our knowledge, this is 
the first time that a splice variant of a tenascin is directly compared to its non-spliced 
counterpart in neurite repulsion and cell migration assays. Differences were found 
between splice variants of TN-C in cell adhesion assays and suggested different and/or 
additional cell binding sites located on the isoforms of TN-C (Prieto et al., 1992). 
Therefore, a possible interpretation of the findings on the different functions of the TN-N 
isoforms in neurite outgrowth and cell migration assays could be that the RGD sequence 
motif in the second FN III domain of TN-N and thus the binding to integrins may be 
masked by the absence of the third FN III homologous repeat. The interaction of TN-C 
and TN-R with integrins via the RGD motif has been well established (for review see: 
Jones and Jones, 2000) and the inhibition of neurite outgrowth by a RGD dependent 
mechanism has been proposed for TN-C (Probstmeier and Pesheva, 1999). Another 
possible model explaining the observed effect is that the contiguity of the second and 
fourth FN III homologous repeat could form a structural motif that is repellent for 
neurites. This motif would not be present if the second and fourth FN III repeats were 
separated by the third FN III repeat, supporting the idea that several receptors or 
interaction partners are responsible for the observed differences of the spliced isoforms of 
TN-N, as described for other tenascins (Joester and Faissner, 2001; Jones and Jones, 2000; 
Prieto et al., 1992). Whether F3/contactin is a receptor for TN-N, as shown for TN-R and 
TN-C, remains to be elucidated. It is noteworthy that in the nervous system TN-N is 
synthesized predominantly by neurons and could thus exert an autocrine function on 
neurite outgrowth. This autocrine function in the adult nervous system could lead to an 
inhibitory environment in a situation where the molecule is present in an inhomogeneous 
extracellular matrix environment, preventing neurite outgrowth under stable conditions. 
Whether TN-N is differentially regulated under conditions of lesion and enhances synaptic 
efficiency, as with TN-C and TN-R, remains a topic for further investigations. 
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2 Conditional gene ablation of tenascin-R 
 
The construction of a floxed TN-R mouse and the conditional gene inactivation in vivo is 
described. 
An important step during the generation of a conditional gene deficient mouse is the 
construction of the targeting vector. To simplify this often complicated procedure, a 
plasmid was constructed with a novel arrangement of a Neo resistance cassette flanked by 
tandemly orientated loxP and FRT sequences. The resulting final plasmid was named 
pJN1 and was additionally equipped with suitable restriction sites for further cloning 
steps. The plasmid pJN1 was tested in a specific targeting project with the purpose of 
generating a conditional knockout mouse model of the tenascin-R gene and its 
functionality was demonstrated. The cassette can be applied to the construction of all kind 
of replacement type targeting vectors and thus facilitates the generation of knockout mice. 
Generally, it is desired to remove the Neo resistance cassette from the genome of ES cells 
after homologous recombination. A frequently observed problem of the Cre mediated 
recombination is that type I deletions between the outermost of three accessible loxP sites 
dominate over the desired type II deletion leading to a floxed allele. Moreover, time 
consuming optimization steps are required to find the correct conditions for Cre mediated 
type II deletions. The pJN1 plasmid offers an alternative to the Cre recombination, since 
the removal of the Neo cassette can be obtained more easily by FLP recombination. In the 
meantime, the restriction of FLP recombination to 30 °C has been overcome by 
mutagenesis and the use of the improved FLP recombinase is a true alternative to the 
application of the Cre recombinase (Buchholz et al., 1998). Depending on the genetic 
context, the presence of the loxP/FRT-Neo-resistance cassette may create a hypomorphic 
allele (Meyers et al., 1998) that can be efficiently converted to the wildtype allele by 
crossing with a FLP expressing deleter mouse strain (Rodriguez et al., 2000), leaving back 
a floxed allele that subsequently can be subjected to restricted gene inactivation by 
crossing with a suitable Cre expressing mouse strain. Moreover, when a new gene is 
targeted, the versatility of this new selection cassette in plasmid pJN1 can be used to 
generate a constitutive and conditional mouse model with only a single targeting vector: 
The same ES cell clone can be treated either with the Cre recombinase to generate a 
constitutive knockout situation or with the FLP recombinase for selective generation of 
the floxed allele needed for conditional applications. 
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The targeting vector constructed and used in this work was a replacement type vector 
including the positive selection marker gene Neo. After homologous recombination and 
removal of the Neo resistance cassette, exon 1 of TN-R was flanked by loxP sites. It was 
chosen to flox exon 1, because it contains the 5’ untranslated region and the 5’ coding 
region of TN-R. Thus, the deletion of exon 1 removes the ribosomal binding site, the 
translation initiation codon, the signal peptide responsible for excretion of TN-R, and a 
large portion of the molecule required for its proper function. Furthermore, possible 
translation initiation codons of exon 2 and 3 are located in wrong reading frames of the 
molecule. Thus, unexpected splicing events in the mutated TN-R gene would lead to 
nonsense proteins. In conclusion, it is highly probable that the deletion of exon 1 leads to a 
complete abolishment of the TN-R expression. 
Working with ES cells requires optimal culturing conditions to prevent the ES cell from 
differentiation. The pluripotent ES cell will efficiently contribute to the developing 
embryo, whereas pre-determined cells only show a low rate of germline transmissions 
(Torres and Kühn, 1997). R1 ES cells were chosen in this work, because it was previously 
reported that they have been successfully applied to other targeting projects (Nagy et al., 
1993). However, an unusually high number of ES cell clones (approximately 1100) had to 
be analyzed to find candidates which had incorporated the targeting vector by homologous 
recombination. In a comparable targeting project in our group in which the same targeting, 
recombination, and culturing conditions have been used, only a few hundred cells had be 
screened to find homologous recombinants. This indicates that the accessibility of the 
targeted gene locus is of importance for the rate of homologous recombination (Haines 
and Brodeur, 1998). The incorporation of the herpes simplex thymidine kinase as a 
negative selection marker together with gancyclovir treatment of the ES cells might have 
improved the selection for homologous recombination (Chen and Bradley, 2000). During 
the selection for clones with a Neo resistance cassette many cells showed a flat 
morphology and started to spread. These ES cells were considered as predetermined or 
differentiated (Torres and Kühn, 1997) and were not picked as single colonies and tested 
for homologous recombination. According to Torres and Kühn (1997), it is likely that this 
strict selection for clones with a round and sharp-bordered morphology contributed to the 
high rate of germline transmission that was observed in this study. 
A tissue specific and time controlled knockout of TN-R was generated by three different 
transgenic mice which were crossed with the floxed TN-R mouse line. The homozygously 
floxed and heterozygously transgenic mice differed from each other by the promoter 
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which regulates the Cre expression. In the first experiments, it was of special interest to 
analyze if the desired recombination event at the TN-R locus occurred. It was shown by 
PCR that in all conditional knockouts the floxed genomic locus of TN-R was recombined 
by the Cre. This recombination deletes exon 1 of TN-R from the genome and leads to an 
abolishment of the protein expression. The reduction in TN-R levels can be detected by 
the monoclonal antibody 596 (Weber et al., 1999). However, only one mouse line, namely 
the TNRWT/FL;CNP-Cre, showed a reduction of the protein by 70 % in adult animals, whereas 
the MOG promoter and PLP promoter controlled Cre transgenic mouse lines were unable 
to reduce the TN-R protein significantly. This observation can be explained by the time-
controlled activity of the three different promoters. MOG and PLP are predominantly 
active during the late phase of oligodendrocyte differentiation (Nave and Lemke, 1991; 
Jaquet et al., 1999; Berndt et al., 2001), whereas the CNP promoter also shows activity in 
oligodendrocyte progenitor cells (Scherer et al., 1994; Gravel et al., 2000). This leads to 
the conclusion that TN-R is predominantly expressed by pre-mature oligodendrocytes and 
is down regulated in finally differentiated cells. The peak in TN-R expression at day 14 of 
mouse development which coincides with the phase of active myelination in the CNS and 
the down regulation to a constant level in the adult are in agreement with this notion 
(Bartsch et al., 1993). 
TN-R is not only expressed by oligodendrocytes, but also by subpopulations of neurons 
(Fuss et al., 1993; Wintergerst et al., 1993). By crossing the MOG, PLP, and CNP 
transgenic mice with the floxed TN-R mouse line, it was aimed to delete TN-R in 
oligodendrocytes only. Thus, it is likely that the remaining TN-R expression in the 
conditional knockout is due to the neuronal protein production. It is a matter of further 
investigations to exclude a mosaic expression profile of the CNP promoter driven Cre 
which could also lead to an incomplete reduction of the TN-R protein. 
The constitutive knockout of TN-R and TN-C showed only mild phenotypes (Weber et al., 
1999; Settles et al., 1997; Forsberg et al., 1996; Mitrovic and Schachner, 1995; Saga et al., 
1992) and did not come up to expectations indicated by many other studies. For example, 
investigations demonstrated anti-adhesive properties of TN-R and TN-C for cell bodies 
and repellent functions on neurite outgrowth (Dorries et al., 1996; Xiao et al., 1996). Even 
functionally specialized domains have been identified and different types of receptors 
interfere with tenascins (Joester and Faissner, 2001). The discrepancy between the 
constitutive knockout phenotype and results from other investigations could be explained 
by regulatory mechanisms which compensate for the lacking molecule (Erickson, 1993; 
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Faissner et al., 1994; Faissner, 1997). This problem might be overcome by conditional 
mutagenesis, allowing normal development of the organism until the spatially restricted 
and time controlled knockout sets in. 
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 Summary 
 
Tenascin-N, a novel member of the tenascin family, was identified by cDNA cloning. 
The total mRNA is 5773 bp in length and was completed by 5’ and 3’ RACE experiments. 
Northern blot analysis confirmed the size of the transcript. Tenascin-N was shown to encode in 
an open reading frame of 4683 bp the characteristic structural motifs of a cysteine-rich stretch, 
3.5 epidermal growth factor-like repeats, 12 fibronectin type III homologous domains, and a 
fibrinogen-like domain. Phylogenetic analysis revealed that tenascin-N is an independent 
homologue of the family and not an orthologue of a known tenascin. In the central nervous 
system, tenascin-N was found to be synthesized predominantly in neurons, but it was most 
highly expressed in specific cell types of kidney, spleen, and bones. The expression pattern 
suggests a predominant localization of tenascin-N to late developmental stages of different 
tissues, since it is produced by a subpopulation of macrophages in the adult spleen, by the 
medullary region of the mature kidney, and by the perichondrial region of later stages of the 
bone development. An alternatively spliced isoform lacking the third fibronectin type III 
homologous domain was identified by RT-PCR analysis. The shorter splice variant repelled 
neurites and migrating neurons from hippocampal CA3 region explant cultures, while the 
longer splice form did not inhibit neurite outgrowth or cell migration. The combined 
observations show that tenascin-N shares functional features with other members of the 
tenascin family. However, although tenascin-N and tenascin-C are expressed in the same 
tissues, the spatial and temporal expression appears to be more complementary than 
overlapping. 
A conditionally targeted mouse line containing a floxed tenascin-R gene was generated 
by homologous recombination in ES cells. To facilitate the construction of the targeting vector, 
a new plasmid that improves the often poor efficiency of the removal of the Neo resistance 
cassette and reduces the risk of unwanted ES cell differentiation was developed and 
functionally tested. For conditional ablation of the tenascin-R gene, three different transgenic 
mouse lines were crossed with floxed tenascin-R mice, in which the transgenic Cre expression 
was controlled by the oligodendrocyte specific MOG, PLP, or CNP promoters. Although the 
recombination at the tenascin-R locus was catalyzed by all transgenic mouse lines, the 
tenascin-R protein was only reduced in the CNP promoter controlled Cre mice. The MOG and 
PLP promoters are predominantly active in mature oligodendrocytes, whereas the CNP protein 
is also produced in oligodendrocyte progenitor cells. This leads to the conclusion that tenascin-
R is predominantly expressed by oligodendrocyte precursor cells. 
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 Zusammenfassung 
 
Tenascin-N, ein bisher unbekanntes Mitglied der Molekülfamilie der Tenascine wurde 
identifiziert und charakterisiert. Die vollständige cDNA enthält 5773 bp und wurde durch 5’ 
und 3’ RACE Experimente komplettiert, wobei Northern-Blot Analysen die Länge des 
Transkripts bestätigten. Der offene Leserahmen der mRNA beträgt 4683 bp und codiert für 
typische Strukturmotive der Tenascine: N-Terminal befindet sich ein cysteinreicher Bereich, 
gefolgt von 3.5 epidermalen, wachstumsfaktorähnlichen Domänen, 12 fibronektinähnlichen 
Domänen und am C-Terminus findet man eine Domäne mit Homologien zu Fibrinogen. 
Phylogenetische Analysen zeigten, daß Tenascin-N ein eigenständiges Homolog der Familie 
darstellt und keine orthologen Verwandtschaften zu bekannten Familienmitgliedern bestehen. 
Im zentralen Nervensystem wird das neue Tenascin vorwiegend von Neuronen gebildet, wobei 
es noch stärker in der Niere, Milz und in Knochen synthetisiert wird. Es tritt besonders in 
späteren Entwicklungsstadien der Gewebe auf. So findet sich Tenascin-N in der Medulla der 
funktionell reifen Niere, in einer Subpopulation der Makrophagen der adulten Milz und in der 
späten Phase der Verknöcherung des Skelettsystems. Eine alternative Splißform von Tenascin-
N wurde durch RT-PCR kloniert. Ihr fehlt die 3. fibrobnektinähnliche Domäne des 
vollständigen Moleküls. In Explantatstudien zeigte sich, daß die kürzere Splißvariante das 
Neuritenwachstum und die Zellwanderung von hippocampalen Neuronen aus der CA3 Region 
inhibiert, wobei sich das vollständige Molekül neutral verhält. Obwohl Tenascin-C und 
Tenascin-N in denselben Organen exprimiert werden, zeigen sie ein zeitlich und räumlich 
unterschiedliches Expressionsmuster. 
Im zweiten Teil dieser Arbeit wird die Etablierung einer Mauslinie vorgestellt, in der 
das Gen für Tenascin-R konditional entfernt wurde. Um die Klonierung des Mutationsvektors 
zu erleichtern, wurde ein neuartiges Plasmid konstruiert, in dem das Neo-Resistenzgen von 
gruppierten LoxP- und FRT-Elementen flankiert wird. Diese Neo-Resistenz-Kassette wurde 
zur Konstruktion der konditionalen Tenascin-R Knockout Mauslinie eingesetzt. In diesen 
Mäusen wurde das Gen für Tenascin-R zelltypspezifisch aus Oligodendrozyten entfernt, indem 
drei unterschiedliche transgene Mauslinien verkreuzt wurden. Diese Linien exprimierten die 
Cre Rekombinase entweder unter der Kontrolle des MOG-, PLP- oder CNP-Promotors. Die 
Rekombination fand in jeder Linie statt, jedoch wurde nur in der Verkreuzung mit der CNP-
Cre Maus das Tenascin-R Protein reduziert. Da die MOG- und PLP-Promotoren erst in der 
späten Phase der Oligodendrozytendifferenzierung aktiv sind, wogegen das CNP-Protein 
bereits in Oligodendrozytenvorläufern vorkommt, führt dies zu der Schlußfolgerung, daß 
Tenascin-R überwiegend in der frühen Entwicklungsphase der Oligodendrozyten gebildet wird. 
                                                                                                                                        Keywords 
90 
 
 Keywords 
 
extracellular matrix 
tenascin family 
conditional knockout 
 
 
 
 Schlagwörter 
 
Extrazelluläre Matrix 
Tenascin 
konditionale Knockout 
 
                                                                                                                      Abbreviation list 
91 
 Abbreviation list 
 
 
aa   amino acid 
bp   base pair 
cDNA   complementary DNA 
CNP   2’,3’-cyclic nucleotide 3’-phosphodiesterase 
E   embryonic day 
ECM   extracellular matrix 
EGF   epidermal growth factor-like 
ES   embryonic stem 
EST   expressed sequence tags 
FBG   fibrinogen-like 
FN III   fibronectin type III 
kD   kilo dalton 
MOG   myelin/oligodendrocyte glycoprotein 
mRNA  messenger RNA 
Neo   aminoglycoside phophotransferase 
P   postnatal day 
PALS   periarterial lymphatic sheath 
PCR   polymerase chain reaction 
PLP   proteolipid protein 
RACE   rapid amplification of cDNA ends 
RGD   arginine-glycine-aspartate 
rpm   round per minute 
RT-PCR  reverse transcriptase PCR 
TN   tenascin 
TNRFL/FL;Cre homozygously floxed TN-R mice + heterozygous Cre transgene 
u   unit 
UTR   untranslated region 
wt   wildtype 
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 Appendix 
 
 
1 The complete cDNA and deduced protein sequence of the  
mouse tenascin-N 
 
 
1    agtaccaggaccagctcacaggaggcagggggattggaagtggtgcccagcagcctcccaggcctcctgg  
                                                                            
71   agtgtctgatccctttctccaagaATGGGTCTCTGGGGGATGCTCGCCTTCCCCCTGGGATTTCTGCTTG  
                              M  G  L  W  G  M  L  A  F  P  L  G  F  L  L  
141  CTTCTGTGCTCCTGGTGGCTTCGGCCCCAGCCACTCCAGAGTCTCCCGGCTGCAGCAACAAAGAGCAACA  
     A  S  V  L  L  V  A  S  A  P  A  T  P  E  S  P  G  C  S  N  K  E  Q  Q  
211  GGTCACTGTTAGCCACACCTACAAGATTGACGTGCCCAAGTCTGCTCTGGTTCAAGTAGAGACCGACCCA  
       V  T  V  S  H  T  Y  K  I  D  V  P  K  S  A  L  V  Q  V  E  T  D  P  
281  CAGTCACTCAGCGATGATGGGACATCACTCTTGGCTCCCGGGGAGGATGGGGAGGAGCAGAACATTATCT  
      Q  S  L  S  D  D  G  T  S  L  L  A  P  G  E  D  G  E  E  Q  N  I  I  
351  TCAGGCACAACATCCGTCTTCAGACACCGCAGAAGAATTGCGACCTGGCAGACAGTGTCCAGGACCTGCT  
     F  R  H  N  I  R  L  Q  T  P  Q  K  N  C  D  L  A  D  S  V  Q  D  L  L  
421  AGCCCGGATGAAAAAGCTGGAGGAAGAGATGGCAGAGCTGAAGGAGCAGTGCAATACCAACCGCTGCTGC  
       A  R  M  K  K  L  E  E  E  M  A  E  L  K  E  Q  C  N  T  N  R  C  C  
491  CAGGGGGCTGCTGATCTGAGCCGTCACTGCAGTGGCCACGGGACCTTCCTCCCTGAGACCTGCAGCTGCC  
      Q  G  A  A  D  L  S  R  H  C  S  G  H  G  T  F  L  P  E  T  C  S  C  
561  ACTGTGACCAGGGCTGGGAGGGCGCAGACTGTGATCAGCCCACCTGTCCTGGGGCTTGCAACGGCCACGG  
     H  C  D  Q  G  W  E  G  A  D  C  D  Q  P  T  C  P  G  A  C  N  G  H  G  
631  GCGCTGTGTGGATGGGCAGTGCGTGTGTGACGCGCCCTATGTGGGGGTCGACTGCGCCTACGCCGCCTGT  
       R  C  V  D  G  Q  C  V  C  D  A  P  Y  V  G  V  D  C  A  Y  A  A  C  
701  CCCCAGGACTGCAGTGGGCATGGCGTGTGCGTGCAGGGTGTCTGCCAGTGCCACGAGGACTTCACAGCAG  
      P  Q  D  C  S  G  H  G  V  C  V  Q  G  V  C  Q  C  H  E  D  F  T  A  
771  AGGACTGCAGCGAGCAGCGCTGTCCTGGCGACTGTAGTGGCAATGGTTTCTGTGACACTGGCGAGTGTTA  
     E  D  C  S  E  Q  R  C  P  G  D  C  S  G  N  G  F  C  D  T  G  E  C  Y  
841  CTGTGAGATGGGCTTTACTGGCCCCGACTGTTCCCAGGTGGTGGCTCCTCAGGGCCTGCAGTTGCTCAAG  
       C  E  M  G  F  T  G  P  D  C  S  Q  V  V  A  P  Q  G  L  Q  L  L  K  
911  AGCACGGAGAACTCTCTGCTGGTGAGTTGGGAGCCCTCCAGTGAGGTAGACTACTACCTGCTCAGCTACT  
      S  T  E  N  S  L  L  V  S  W  E  P  S  S  E  V  D  Y  Y  L  L  S  Y  
981  ACCCCCTGGGGAAGGAGCAAGCTACAAAACAGGTCCGGGTACCCAAGGAGCAGCACACCTATGACATCAC  
     Y  P  L  G  K  E  Q  A  T  K  Q  V  R  V  P  K  E  Q  H  T  Y  D  I  T  
1051 CGGCTTGCTGCCTGGAACCAAGTACATAGTCACCCTGCGCAACGTGAAGAAAGACATTTCCAGCAGCCCT  
       G  L  L  P  G  T  K  Y  I  V  T  L  R  N  V  K  K  D  I  S  S  S  P  
1121 CAGCATCTACTTGCCACCACAGATCTTGCTGTGGTGGGCACAGCCTGGGTAAATGAAGAGACTGAGACAT  
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      Q  H  L  L  A  T  T  D  L  A  V  V  G  T  A  W  V  N  E  E  T  E  T  
1191 CCCTCGATGTGGAGTGGGAGAACCCTCTGACTGAGGTGGACTATTACAAGCTTCGGTATGGCCCCTTAAC  
     S  L  D  V  E  W  E  N  P  L  T  E  V  D  Y  Y  K  L  R  Y  G  P  L  T  
1261 AGGGCAGGAGGTGACAGAGGTCACTGTGCCCAAGAGCCGTGATCCCAAGAGCAGATATGACATCACTGGT  
       G  Q  E  V  T  E  V  T  V  P  K  S  R  D  P  K  S  R  Y  D  I  T  G  
1331 CTGCAGCCTGGAACGGAATATAAAATCACAGTTGTGCCCATCCGAGGTGATCTGGAGGGAAAGCCGATTC  
      L  Q  P  G  T  E  Y  K  I  T  V  V  P  I  R  G  D  L  E  G  K  P  I  
1401 TCCTGAATGGCAGGACAGAAATTGATGGACCAACCAATGTGGTCACAAATCAGGTGACAGAAGACACAGC  
     L  L  N  G  R  T  E  I  D  G  P  T  N  V  V  T  N  Q  V  T  E  D  T  A  
1471 ATCTGTTTCCTGGGATCCAGTGAGGGCTGACATAGACAAGTATGTGGTGCGCTATATCGCCCCTGATGGG  
       S  V  S  W  D  P  V  R  A  D  I  D  K  Y  V  V  R  Y  I  A  P  D  G  
1541 GAGACCAAGGAGAAGGCAGTACCAAAGGACCAGAGCAGCACCGTTCTCACAGGCCTGAAGCCAGGAGAGG  
      E  T  K  E  K  A  V  P  K  D  Q  S  S  T  V  L  T  G  L  K  P  G  E  
1611 CCTACAAAGTCTTTGTGTGGGCTGAGAGGGGCAACCAAGGCAGCAAGAAAGCAGACACCAAGGCCCTCAC  
     A  Y  K  V  F  V  W  A  E  R  G  N  Q  G  S  K  K  A  D  T  K  A  L  T  
1681 AGAAATTGACAGTCCAGAAAACCTGGTGACTGACCGGGTGACAGAGAACAGCCTCTCTGTCTCGTGGGAC  
       E  I  D  S  P  E  N  L  V  T  D  R  V  T  E  N  S  L  S  V  S  W  D  
1751 CCAGTGGAGGCTGACATCGACAGGTACGTGGTAAGCTACACTTCCGTGGATGGAGAGACGAAGCAGGTTC  
      P  V  E  A  D  I  D  R  Y  V  V  S  Y  T  S  V  D  G  E  T  K  Q  V  
1821 CAGTGAAGAAGGACCAGAGGAGCACCGTCCTCACCGGCCTGAGTCCCGGTGTGGAGTACAAAGTTTACGT  
     P  V  K  K  D  Q  R  S  T  V  L  T  G  L  S  P  G  V  E  Y  K  V  Y  V  
1891 GTGGGCAGAGAAAGGCGATCGGGAGAGCAAGAAGGCCAACACCAAGGCTCCCACAGACATCGACAGCCCC  
       W  A  E  K  G  D  R  E  S  K  K  A  N  T  K  A  P  T  D  I  D  S  P  
1961 AAAAACTTGGTAACTGACCAGGTGACAGAGAACACTCTCAGTGTCTCCTGGGACCCTGTTCAGGCCAACA  
      K  N  L  V  T  D  Q  V  T  E  N  T  L  S  V  S  W  D  P  V  Q  A  N  
2031 TTGACAGGTATATGGTGAGCTACACCTCTGCCGATGGAGAGACAAGAGAGGTCCCAGTGCCTAAGGAGAA  
     I  D  R  Y  M  V  S  Y  T  S  A  D  G  E  T  R  E  V  P  V  P  K  E  K  
2101 GAGCAGTACCGTCCTGACTGGCCTGAGGCCAGGTGTGGAGTACAAGGTCCATGTGTGGGCCCAGAAGGGG  
       S  S  T  V  L  T  G  L  R  P  G  V  E  Y  K  V  H  V  W  A  Q  K  G  
2171 ACCCAGGAGAGCAGAAAGGCCAACACCAAGGCCCCCACAGATATTGATGGCCCCAAAAACCTGGTGACTG  
      T  Q  E  S  R  K  A  N  T  K  A  P  T  D  I  D  G  P  K  N  L  V  T  
2241 ACCAGGTGACCGAGACCACTCTTAGTGTCTCCTGGGACCCAGTGGAGGCTGACATTGATAGGTACATGGT  
     D  Q  V  T  E  T  T  L  S  V  S  W  D  P  V  E  A  D  I  D  R  Y  M  V  
2311 TCGCTACACGTCTCCTGATGGAGAGACCAAGGAGGTGCCTGTGTCAAAGGATAAGAGCAGCACAGTCCTG  
       R  Y  T  S  P  D  G  E  T  K  E  V  P  V  S  K  D  K  S  S  T  V  L  
2381 AGGGGCCTGAGGCCAGGTGTGGAGTACAAGGTGGATGTATGGGCCCAGAAGGGGGCCCAGGACAGCCGGA  
      R  G  L  R  P  G  V  E  Y  K  V  D  V  W  A  Q  K  G  A  Q  D  S  R  
2451 AGGCCAACACCAAGGCCCCCACAGATATTGACAGCCCTAAAAACCTGGTGACTGAGCAGGTGACAGAGAG  
     K  A  N  T  K  A  P  T  D  I  D  S  P  K  N  L  V  T  E  Q  V  T  E  S  
2521 CACTGCCACCGTGTCCTGGGACCCAGTAGAGGCTGACATCGACAGGTATGTGGTGCGCTACACTTCTGTC  
       T  A  T  V  S  W  D  P  V  E  A  D  I  D  R  Y  V  V  R  Y  T  S  V  
2591 GATGGCGAGACCAGGGAATTTCTCGTTGGGAAGGACCAAACAAGCACCGTCCTGACAGGCATGAGACCAG  
      D  G  E  T  R  E  F  L  V  G  K  D  Q  T  S  T  V  L  T  G  M  R  P  
2661 GTGTGGAGTATCAGGTCGACGTGTGGGCCCAGAAGGGGACACAGGAAAGCAGGAAGACCAGCACCAAAGC  
     G  V  E  Y  Q  V  D  V  W  A  Q  K  G  T  Q  E  S  R  K  T  S  T  K  A  
2731 CCCAACAGATATTGATGGCCCCAAAAACCTGGTGACTGACCAGGTGACCGAGACCACTCTTAGTGTCTCC  
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       P  T  D  I  D  G  P  K  N  L  V  T  D  Q  V  T  E  T  T  L  S  V  S  
2801 TGGGACCCAGTGGAGGCTGACATTGATAGGTACATGGTTCGCTACACGTCTCCTGATGGAGAGACCAAGG  
      W  D  P  V  E  A  D  I  D  R  Y  M  V  R  Y  T  S  P  D  G  E  T  K  
2871 AGGTGCCTGTGTCAAAGGATAAGAGCAGCACAGTCCTGAGGGGCCTGAGGCCAGGTGTGGAGTACAAGGT  
     E  V  P  V  S  K  D  K  S  S  T  V  L  R  G  L  R  P  G  V  E  Y  K  V  
2941 GGATGTATGGGCCCAGAAGGGGGCCCAGGACAGCCGGAAGGCCAACACCAAGGCCCCCACAGATATTGAT  
       D  V  W  A  Q  K  G  A  Q  D  S  R  K  A  N  T  K  A  P  T  D  I  D  
3011 AGTCCCAAAAACCTGGCGATCGACCAGGTGACAGAGACCACTCTCAGTGTCTCCTGGGACCCAGTACAGG  
      S  P  K  N  L  A  I  D  Q  V  T  E  T  T  L  S  V  S  W  D  P  V  Q  
3081 CTGACATTGACAGGTATGTGGTGCGCTACACCTCTGCTGATGGGGAATCCAAAGAATTCCTGATTGGGAA  
     A  D  I  D  R  Y  V  V  R  Y  T  S  A  D  G  E  S  K  E  F  L  I  G  K  
3151 GGAACAGAGGAGCACAGTCCTGACAGGCCTGAGGCCAGGTGTGGAGTACAAGGTTGAAGTGTGGGCCCAG  
       E  Q  R  S  T  V  L  T  G  L  R  P  G  V  E  Y  K  V  E  V  W  A  Q  
3221 AAAGGAGCCCGGGAGAGCAAGAAAGCCAACACCGAAGGTCACACAGACATTGACAGCCCCAAAAACCTGG  
      K  G  A  R  E  S  K  K  A  N  T  E  G  H  T  D  I  D  S  P  K  N  L  
3291 TGACCAATCAGGTGACCGAAAATACAGCCACCATCTCCTGGGACCCGGTGCAGGCTGATATTGACAGATA  
     V  T  N  Q  V  T  E  N  T  A  T  I  S  W  D  P  V  Q  A  D  I  D  R  Y  
3361 CATGGTGCGCTACACATCTGCTGATGGAGAGACCAGGGAGATTCCAGTGAGGAAGGAGAAGAGCAGCACT  
       M  V  R  Y  T  S  A  D  G  E  T  R  E  I  P  V  R  K  E  K  S  S  T  
3431 GTCCTCACAGGCCTGAGACCGGGTGTGGAGTACACGGTCCAAGTGTGGGCTCAGAAGGGGGCCCGGGAGA  
      V  L  T  G  L  R  P  G  V  E  Y  T  V  Q  V  W  A  Q  K  G  A  R  E  
3501 GCAAGAAGGCCAAAACCAAGGCCCCCACAGAAATTGACAGCCCCAAGAACTTGGTGACCAACCGAGTGAC  
     S  K  K  A  K  T  K  A  P  T  E  I  D  S  P  K  N  L  V  T  N  R  V  T  
3571 AGAAAATACAGCCACCATCTCCTGGGACCCAGTGCGAGCCAACATTGACAGGTACATGGTTCGCTACACC  
       E  N  T  A  T  I  S  W  D  P  V  R  A  N  I  D  R  Y  M  V  R  Y  T  
3641 TCTGCGGATGGAGAGACTAAGGAGATTCCAGTGTCAAAGGATCAGAGTAGCACCATCCTGACAGGCCTGA  
      S  A  D  G  E  T  K  E  I  P  V  S  K  D  Q  S  S  T  I  L  T  G  L  
3711 AACCAGGCATGGAATATACCATTCATGTGTGGGCCCAGAAGGGGCCCCGGGAGAGCAAGAAGGCTGATAC  
     K  P  G  M  E  Y  T  I  H  V  W  A  Q  K  G  P  R  E  S  K  K  A  D  T  
3781 CAAGGCCCTAACAGAAATTGACCCTCCCAGAAATCTCCGTCCGTTCGGGGTAACACATTCTGGTGGGGTT  
       K  A  L  T  E  I  D  P  P  R  N  L  R  P  F  G  V  T  H  S  G  G  V  
3851 TTGACCTGGTTGCCCCCATCTGCTCAAATTGATGGCTACATTTTGACCTACCAGTTCCCAAATGGCACCG  
      L  T  W  L  P  P  S  A  Q  I  D  G  Y  I  L  T  Y  Q  F  P  N  G  T  
3921 TGAAGGAGGTGGAGCTCCCAAGAGGCCAGCAGAGATTTGAATTGCAAGACCTGGAACAGGGTGTCACCTA  
     V  K  E  V  E  L  P  R  G  Q  Q  R  F  E  L  Q  D  L  E  Q  G  V  T  Y  
3991 TCCTGTTTCCTTGGTTGCCTTCAAAGGTAATCAGCGGAGCCGGACTGTGTCTACCACCCTTTCTACAGTG  
       P  V  S  L  V  A  F  K  G  N  Q  R  S  R  T  V  S  T  T  L  S  T  V  
4061 GATGCTCGCTTTCCACACCCCTCAGACTGCAGTCAAGTTCAGCAGAACACCAACGCTGCCAGTGGGCTCT  
      D  A  R  F  P  H  P  S  D  C  S  Q  V  Q  Q  N  T  N  A  A  S  G  L  
4131 ACACCATCTACCTCAATGGTGATGCCAGCCGGCCCATGCAGGTGTACTGCGACATGGACACCGACGGAGG  
     Y  T  I  Y  L  N  G  D  A  S  R  P  M  Q  V  Y  C  D  M  D  T  D  G  G  
4201 CGGCTGGATTGTCTTCCAGAGACGGAACACTGGGCAGCTGGATTTCTTCAAGCGTTGGCGGAGTTATGTA  
       G  W  I  V  F  Q  R  R  N  T  G  Q  L  D  F  F  K  R  W  R  S  Y  V  
4271 GAAGGTTTTGGGGACCCCATGAAGGAGTTCTGGCTTGGACTTGATAAACTACATAATCTCACCACTGGCA  
      E  G  F  G  D  P  M  K  E  F  W  L  G  L  D  K  L  H  N  L  T  T  G  
4341 CCACCACTCGGTATGAGGTGAGGGCAGACTTACAGACTTTCAATGAATCTGCCTACGCTGTATATGATTT  
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     T  T  T  R  Y  E  V  R  A  D  L  Q  T  F  N  E  S  A  Y  A  V  Y  D  F  
4411 CTTCCAAGTGGCATCCAGCAAAGAGCGGTACAAGCTGTCGGTTGGGAAATACAGAGGCACAGCCGGGGAT  
       F  Q  V  A  S  S  K  E  R  Y  K  L  S  V  G  K  Y  R  G  T  A  G  D  
4481 GCTCTCACCTACCACAATGGATGGAAGTTCACGACTTTTGACAGAGACAATGATATTGCCCTCAGCAACT  
      A  L  T  Y  H  N  G  W  K  F  T  T  F  D  R  D  N  D  I  A  L  S  N  
4551 GTGCACTGACGCATCATGGTGGCTGGTGGTATAAGAACTGCCATTTGGCCAACCCGAATGGCAAATATGG  
     C  A  L  T  H  H  G  G  W  W  Y  K  N  C  H  L  A  N  P  N  G  K  Y  G  
4621 GGAGACCAAGCACAGCGAGGGGGTGAACTGGGAGCCATGGAAGGGACATGAGTTCTCCATTCCTTATGTG  
       E  T  K  H  S  E  G  V  N  W  E  P  W  K  G  H  E  F  S  I  P  Y  V  
4691 GAGCTGAAAATCCGCCCGTTTGGTTACAGCAGAGACCGTTTCTCTGGCAGAAAGAAGCGCTCCATAGGAA  
      E  L  K  I  R  P  F  G  Y  S  R  D  R  F  S  G  R  K  K  R  S  I  G  
4761 AAGCAAGGATGTTCTGAaggcttgtctgagctgtcttcacaggagacaagagaaacttggggttggcggg  
     K  A  R  M  F  *   
4831 gtagatggtgcctaggaagctgaagtttgagggatgctcatagcctccgacttcctagattgctgggtac  
 
4901 acagtgctaatgacgtcatcacactttgacctttagaggttccttccatgtcatctgcaagtttgactgt  
 
4971 ctctactgagggcttcattgttggctttcaggagccaacaatgttgtaactgaacagtacatatggatag  
 
5041 aacacgtgttggaatcacaaggttttttcagcccatccttaatgacagatgtattgaattagggcaaaaa  
 
5111 ggtgaaccatcctgtagaccatcaattggaaatctttagaaattggtggagatctctgtatccatctgat  
 
5181 aatatagatctttgtagaaaaaaaaagacaaagtgaggttctgatcccctgggtgtcagagctgaggcga  
 
5251 cctgctacttcttgtctctcctggacctcctggtgtttgaaggaaatgtttatatcttactacttttaaa  
 
5321 cttcctgtgtgatgaagaatgaagagactacaaaggggccacgatgcagtcatagttaagttctgactag  
 
5391 tctctagcattctagagaccaaagctcccattttattgctatttttaactgccccttttccagacatttg  
 
5461 cataagttctttcatagatctgcatatgttgtaaataaatttgcagtcatttaaactttaaataacccat  
 
5531 ctctttaaataactggtcccctcagctcccccccaccacttcactcacctccatgcctctcccctccccc  
 
5601 gggtccatcagccctcagactccctccttccctgctccccacactggaagcttcctcacatcatctttct  
 
5671 tgcgtgtttggtgtcattttggaaagttttctgtaaccaagtcagtgacctttgaagtaacttaaattcc  
 
5741 tactcaagaaaacacaaataaactgtttgattt  
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